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Resumo 
 
 
 
 
A lichenicidina é um lantibiótico de classe II, naturalmente 
produzido por B. licheniformis I89. É constituída por dois péptidos 
denominados Bliα e Bliβ. Este lantibiótico foi o primeiro a ser 
expresso completamente in vivo num hospedeiro Gram negativo 
(Escherichia coli).  
Neste trabalho, pretendeu-se avaliar o impacto da proteína LicR 
na biossíntese da lichenicidina usando um sistema de expressão 
heteróloga em E. coli. A estirpe de E. coli que não contem o gene 
licR parece apresentar uma maior produção de lichenicidin do que a 
estirpe que contem todo o conjunto de genes envolvidos na síntese 
da lichenicidin. Assim, LicR parece não apresentar qualquer função 
regulatória em E. coli ou esta não poderá ser descrita segundo os 
mecanismos habituais de regulação da produção de lantibióticos. 
Paralelamente um sistema de expressão foi construído para produzir 
cada um dos péptidos da lichenicidina separadamente, tendo sido 
comparados os níveis de produção de cada um dos péptidos. Este 
sistema foi usado com sucesso para produzir o péptido Bliβ mas 
não apresentando qualquer vantagem sobre os sistemas ao nível da 
produção. Finalmente, uma biblioteca de mutagénese do péptido 
Bliα foi construída em E. coli e os clones obtidos foram analisados; 
a maioria dos clones obtidos apresentou bioatividade reduzida ou 
nula contra Micrococcus luteus. Alguns destes clones foram 
sequenciados para determinar qual(ais) a(s) mutação(ões) 
presente(s) no gene licA1.  
 
  
 
 
 
 
Keywords 
 
 
Lichenicidin, lantibiotics, heterologous expression, peptide 
engineering, biosynthesis regulation, random mutagenesis 
 
Abstract 
 
 
 
 
Lichenicidin is a class II lantibiotic, naturally produced by 
Bacillus licheniformis I89 strain. It is composed by two peptides: 
Bliα and Bliβ. This was the first lantibiotic to be fully produced in 
vivo using a Gram negative host (Escherichia coli).  
Herein, the impact of LicR protein in lichenicidin biosynthesis 
was assessed, using an E. coli heterologous expression system. It 
was shown that the E. coli strain without the licR gene presented 
increased lichenicidin production, when compared with the strain 
containing the entire gene cluster. Thus, if LicR presents some 
regulatory function in E. coli, its role cannot be described according 
to the usually proposed regulation mechanisms involved in 
lantibiotic production. Also, an expression system was constructed 
to produce each lichenicidin peptide independently and this 
expression system was compared with other available systems in 
terms of production levels. The system was successfully used to 
obtain Bliβ peptide. However it did not show any advantage over 
the systems previously developed. Ultimately, a mutagenesis library 
of Bliα was constructed in E. coli and the clones were analyzed; the 
majority of the clones showed low or null bioactivity against 
Micrococcus luteus. Some of these clones were sequenced to 
determine which mutation(s) was present in the licA1 gene. 
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Nowadays, search for novel compounds that can be useful in the treatment of 
bacterial infections is an important objective for the scientific community. The 
increasing capacity of bacteria to develop resistance leads to the inefficacy of the 
common antibiotics. Therefore, it is important to discover new compounds that are 
active against a large range of bacterial species (Donaghy, 2010, Gyssens, 2011).  
In this context, a new type of antimicrobial peptides, the so-called lantibiotics, was 
discovered. These compounds are now under intense investigation in order to 
characterize and understand their biosynthesis and mode of action. They show activity 
against a large number of Gram positive bacteria, including the methicilin-resistant 
Staphylococcus aureus (MRSA), vancomycin-resistant enterococci and oxacillin-
resistant Gram positives (Bierbaum & Sahl, 2009, Field, et al., 2010).  
1.1 Lantibiotics  
Lantibiotics are antimicrobial peptides, ribosomally synthesized by some Gram 
positive bacteria. They contain several unusual amino acids in their structure that result 
from enzyme mediated post-translational modifications (Figure 1). These peptides have 
particular interest because they can be much more potent against Gram-positive targets 
(including many antibiotic-resistant pathogens), than classical antibiotics, since they 
have the essential cell wall precursor lipid II as target. Another important feature is 
related with the fact that they are gene encoded (ribosomal synthesis), meaning that they 
can be more easily engineered to enhance their action (Field, et al., 2010).  
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Lantibiotics are characterized by the presence of post-translationally generated 
thioether linkages known as lanthionines (Lan) or β-methyllanthionines (MeLan), from 
where its denomination was originated (lanthionine-containing antibiotics) (Field, et al., 
2010). The active peptides and all the enzymes associated with their modification are 
gene-encoded. Their biosynthesis begins with the production of a prepropeptide. The 
prepropeptide (also known as prepeptide) is an inactive form of the lantibiotic, where 
none of the residues are modified (Figure 2). The prepropeptide can be divided in two 
regions: the N-terminal leader sequence and the C-terminal propeptide (Willey & Donk, 
2007). 
  
Figure 1 - Representation of the post-translational modifications involved in the biosynthesis 
of the lantibiotic nisin (Nagao, et al., 2006). 
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Figure 2 - Representation of the prepropeptide of the lantibiotic nisin (Willey & Donk, 2007). The leader 
sequence is represented in blue and the propeptide in red. Adapted from (Willey & Donk, 2007). 
 
The leader sequence most probably promotes the transport of the peptide across the 
membrane by interacting with specific transporters. Moreover, it may be also important 
to keep the lantibiotic inactive until its secretion. Just immediately before or during the 
secretion process, the leader sequence is removed by a specific protease and the 
modified peptide becomes biologically active (Oppergard, et al., 2007). Besides, the 
leader sequence seems to be necessary for the correct action of the modification 
enzymes. However, it is known that some peptide tags can be added to the leader 
sequence without affecting post-translational modifications (Nagao, et al., 2006). The 
formation of the Lan and MeLan rings occurs exclusively in the propeptide region. The 
majority of the serines and threonines that are present in this area are enzymatically 
dehydrated to dehydroalanine (Dha) and dehydrobutyrine (Dhb), respectively (Figure 
3). Sequentially, a cyclase catalyzes the regio- and stereoselective Michael additions of 
a cysteine onto Dha and Dhb amino acids, forming the Lan and MeLan thioether 
crosslinks correspondingly (Willey & Donk, 2007). The presence of this bridges convert 
the linear peptide into a polycyclic form, conferring not only structure and function to 
the peptide but also providing proteolytic resistance and increasing tolerance to 
oxidation (Field, et al., 2010). 
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Figure 3 – Representation of the Lan and MeLan thioether ring formation in lantibiotics (Willey & Donk, 2007). 
The general designation of the genes constituting the biosynthetic cluster is lan 
followed by a capital letter indicating the specificity of the gene. This general 
designation can be changed to a more specific nomenclature according to the lantibiotic 
that is being considered. For example, the genes involved in lacticin 3147 and nisin 
biosynthesis are designated as ltn and nis, respectively. The genes encoding all the 
enzymes involved in lantibiotic biosynthesis are usually found in clusters, which can be 
located in the chromosome (e.g. subtilin) or in mobile genetic elements such as 
transposons and/or plasmids (e.g. nukacin ISK-1) (Guder, et al., 2000, Nagao, et al., 
2006, Willey & Donk, 2007). This localization seems to have no relation with the 
subtype grouping of lantibiotics (Nagao, et al., 2006). All the gene clusters possess a 
lanA structural gene, which encodes the prepropeptide as well as other enzymes 
required for post-translational modification (lanB, lanC, lanM), leader peptide removal 
and peptide transport (lanP, lanT). Other genes involved in regulation (lanR, lanK) 
and/or immunity (lanF, lanG, lanE, lanH, lanI) may also be found within the 
biosynthetic cluster or in other closely related clusters (Guder, et al., 2000, Willey & 
Donk, 2007). 
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1.1.1. Classification of lantibiotics 
There are two main classification schemes used to group all the known lantibiotics: the 
Jung´s (Guder, et al., 2000, Nagao, et al., 2006) and the Pag & Sahl classifications (Pag & 
Sahl, 2002, Willey & Donk, 2007).  
Pag & Sahl scheme will be adopted in the present work and is based on the pathway by 
which maturation of the peptide occurs as well as its biological activity (Pag & Sahl, 2002, 
Willey & Donk, 2007). According to this classification, the lantibiotics can be divided in 
three classes, which will be described in the following sections (Figure 4). 
 
Figure 4 – Representation of the main differences between classes I, II and III lantibiotics, concerning the 
enzymes involved in modification, leader peptide processing and transport. 
 
1.1.1.1 Class I 
In class I lantibiotics, the prepropeptides are modified by two different enzymes: the 
LanB dehydratase and the LanC cyclase that mediates the thioether ring formation. The 
leader sequence removal and export of the peptide are performed also by two different 
enzymes: the subtilisin-like serine protease, LanP, and the ABC transporter, LanT. This 
class comprises the lantibiotics nisin and subtilin (Figure 5) and other related peptides. 
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Figure 5 – Structures of representative examples of class I lantibiotics: nisin and subtilin (Willey & Donk, 2007). 
 
1.1.1.2 Class II 
In class II lantibiotics, the prepropeptides are modified by the LanM single enzyme, 
exhibiting both dehydratase and cyclase activities. LanM proteins do not show any 
homology to LanB proteins and have low sequence identity to LanC enzymes. Secretion 
and leader processing are performed by a single multifunctional protein that also shares 
the LanT designation. This class comprises the lantibiotics lacticin 481 and mersacidin 
(Figure 6), cinnamycin, duramycins and two-component lantibiotics (Willey & Donk, 
2007, Field, et al., 2010). 
 
Figure 6 – Structures of representative examples of class II lantibiotics: lacticin 481 and mersacidin (Willey & 
Donk, 2007). 
 
1.1.1.3 Two-component lantibiotics 
The two-component lantibiotics are constituted by two peptides, which act 
synergistically to exhibit antimicrobial activity. Both peptides have a specific role in 
antimicrobial activity.  Each of the peptides is encoded by its own structural gene and 
modified by separate LanM enzymes. However, a single LanT removes the leader 
sequence and secrete both peptides. In general terms, the two structural genes as well as 
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the two lanM genes are adjacent to each other in the same cluster, but in opposite 
directions (Figure 7) (Willey & Donk, 2007, Oman & van der Donk, 2009). 
 
Figure 7 – Examples of the two-component lantibiotics haloduracin and lacticin 3147 gene clusters. Adapted 
from (Lawton, et al., 2007) and (Willey & Donk, 2007), respectively. A1 and A2 represent the structural genes while 
M1 and M2 encode the respective modification enzymes; J encodes other enzyme which is necessary for the correct 
lacticin modification; R is a putative regulatory gene; T is the gene encoding the transporter protein; finally, F, G, E 
and I represent the immunity genes. 
 
Historically, the unmodified peptides are designated LanA1 and LanA2, whereas the 
mature peptides are designated by the Greek symbols: Lanα and Lanβ. These peptides 
have diverse characteristics in common with one-peptide lantibiotics; they usually are 
cationic, containing hydrophobic and/or amphiphilic regions. Some examples of two-
component lantibiotics include: plantaricin W, staphylococcin C55, cytolysin L, lacticin 
3147 and haloduracin (Figure 8) (Willey & Donk, 2007, Field, et al., 2010) and also the 
case of study, lichenicidin. 
 
Figure 8 – Structures of representative examples of class II two-component lantibiotics: lacticin 3147 (A1 and 
A2) and haloduracin (α and β) (Willey & Donk, 2007). 
 
The sequence homology between both peptides is low. In fact, the mature peptides of 
several two-component systems share structural and sequence homology with known 
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single-peptide lantibiotics but not with its own complementary one. Usually, mature α-
peptides resemble the globular lantibiotic mersacidin with several fused thioether rings, 
while the mature β-peptides are typically elongated and more flexible (Oman & van der 
Donk, 2009). 
 
1.1.1.4 Class III 
This class comprises lanthionine-containing peptides that lack significant antibiotic 
activity; instead they perform another functions (e.g. as inhibition of phospholipase A2, 
biosurfactant activity, virulence factors) for the producing cell as is the case of AmfS 
produced by Streptomyces griseus, SapB (Figure 9) produced by Streptomyces 
coelicolor (Kodani, et al., 2004) and SapT (Figure 9) produced by Streptomyces tendae 
(Kodani, et al., 2005, Willey & Donk, 2007, Field, et al., 2010). Labyrinthopeptins are 
also included in this class and can be distinguished by the presence of labionin, which is 
a carbacyclic, post-translationally modified amino acid derived from the activity of the 
enzyme LabKC on Ser-Xxx-Xxx-Ser-Xxx-Xxx-Xxx-Cys motifs in the corresponding 
propeptides (Field, et al., 2010). 
 
Figure 9 – Structures of representative examples of class III lantibiotics: SapB and SapT (Willey & Donk, 2007). 
 
1.1.2 Biological activity of lantibiotics 
As abovementioned, some lantibiotics are bactericidal at nanomolar concentrations 
against a variety of Gram positive bacteria, including the MRSA, (Willey & Donk, 
2007, Bierbaum & Sahl, 2009). Lantibiotics have two main targets in the bacterial cell: 
the cell-wall intermediate lipid II and the cytoplasmic membrane. Nisin, a class I 
lantibiotic, exerts its activity on both of these components: its two N-terminal thioether 
rings form a binding pocket also called the pyrophosphate cage, which is stabilized by 
hydrogen bonds. This cage envelops the undecaprenyl pyrophosphate moieties of the 
lipid II molecule. After binding to lipid II, the positively charged C-terminus is able to 
insert into the membrane, oligomerize and form a pore that contains eight nisin 
molecules and four lipid II molecules (Figure 10) (Bierbaum & Sahl, 2009).  
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Considering the class II two-component lantibiotics, each of the peptides individually 
can have some antimicrobial activity, but at low levels. However, high activity (from 
pico to nanomolar concentrations) is only reached if the two-peptides are combined, 
since they act synergistically to inhibit the growth of other Gram positive bacteria. Their 
general mode of action is illustrated by the lacticin 3147 lantibiotic (Ltnα and Ltnβ): it 
has been proposed that the α-peptide binds to lipid II thereafter, the β-peptide is able to 
recognize this complex and bind it, subsequently inserting into the cytoplasmic 
membrane and forming a pore (Figure 10) (Bierbaum & Sahl, 2009) 
 
Figure 10 – General description of the mode of action of lantibiotics. A cytoplasmic membrane (black circles) 
with the lipid II attached is represented. In (A), the lantibiotic molecule binds to the head group of lipid II; in (B) 
nisin attaches to lipid II with its N-terminus and subsequently inserts into the membrane and forms a pore consisting 
of 4 lipid II and 8 nisin molecules (C); in (D) pore formation by a two-peptide system is shown: the α-peptide binds 
to lipid II and the β-peptide forms the pore (Bierbaum & Sahl, 2009). 
However, as referred, not all the lantibiotics are antimicrobials. For instance, the 
two-component lantibiotic cytolysin, not only targets other Gram positives, but also 
functions as a virulence factor, lysing erythrocytes and polymorphonuclear leukocytes 
(Cox, et al., 2005, Willey & Donk, 2007). In class III lantibiotics, potent inhibitors of 
phospholipase A2 (cinnamycin) can be found, but also peptides that can increase the 
chloride secretion in lung epithelium (duramycin) (Marki, et al., 1991, Willey & Donk, 
2007). Moreover, SapB and SapT are both hydrophobic and surface active peptides, 
function as biosurfactants, that release the surface tension at the colony-air interface 
(Kodani, et al., 2004, Kodani, et al., 2005, Willey & Donk, 2007). 
 
1.1.3 Regulation of lantibiotic biosynthesis 
In most cases, lantibiotic production is an adaptive advantage, and so, it is regulated 
by the presence of other microorganisms or other adverse environmental conditions. It 
could also be useful for the uptake of homologous DNA when associated with 
competence development, by selectively targeting non-competent cells of the same 
strain (Willey & Donk, 2007). Lantibiotic production is often regulated with other 
cellular events and takes place usually in the late exponential growth phase (Chatterjee, 
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et al., 2005, Willey & Donk, 2007). Biosynthesis of several lantibiotic and 
nonlantibiotic peptides seems to be regulated by typical bacterial two-component 
regulatory systems using the molecule itself as trigger, functioning as quorum sensing 
molecules (Guder, et al., 2000). 
The regulation of several lantibiotics biosynthesis has been studied. For instance, 
autoregulation of nisin and subtilin is performed by sub inhibitory concentrations of 
these class I lantibiotics in the extracellular environment. This was found to initiate a 
kinase/response regulatory signal transduction system that increments the transcription 
of biosynthetic and immunity genes. Usually these mechanisms are active during mid-
exponential growth of the cell and they reach a peak of production at the log- to 
stationary-phase transition (Willey & Donk, 2007). In the case of subtilin, regulation 
depends on the transcription of the spaRK operon, which encodes the response regulator 
(spaR) and the signal kinase (spaK). The transcription of this operon is also regulated 
and dependent on the alternative sigma factor, σH, which is regulated at transcriptional 
and translational levels (Stein, et al., 2002, Willey & Donk, 2007).  
Concerning Bacillus sp. HILY-85 strain, it seems to coordinately regulate mersacidin 
(class II lantibiotic) biosynthesis with other stationary-phase events and in fact, the 
peptide is not produced until the beginning of the stationary phase. Contrarily to 
subtilin, this process is σH-independent. It was also observed that mersacidin gene 
cluster encodes two different response regulators MrsR1 and MrsR2/MrsK2. 
MrsR2/MrsK2 complex regulates the transcription of the self-immunity genes, whereas 
MrsR1 is exclusively involved in the production of the peptide itself. Synthesis of 
mersacidin seems not to be autoregulatory but controlled by a so-called orphan response 
regulator without a dedicated kinase (Schmitz, et al., 2006, Sass, et al., 2008). Other 
examples of this system include the lantibiotics lacticin 3147, mutacin II, epidermin and 
SapB (Willey & Donk, 2007).  
The regulation of epidermin, a lantibiotic produced by Staphylococcus epidermidis, 
is in part controlled by global cellular stress response regulators and biofilm formation. 
The EpiQ protein, encoded in the epidermin biosynthetic cluster, regulates the 
transcription of the epiA structural gene. However, EpiP production, necessary for the 
removal of epidermin leader sequence, is under the control of the global regulatory 
system agr (Willey & Donk, 2007).  
Another example of regulation mechanisms can be found in the production of 
lacticin 481 by Lactococcus lactis strains, which is regulated by two promoters, P1 and 
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P3; the expression of the genes under the control of these promoters is stimulated by 
acidification of the medium due to the presence of lactic acid. The co-transcription with 
a universal stress-like protein and a multidrug transporter leads to an increase of acid 
tolerance (Willey & Donk, 2007).  
Focusing on the mechanism that regulates the production of the two-component 
lantibiotics, the best well-characterized system is that of cytolysin (CylLS and CylLL). 
Cytolysin works as an Enterococcus faecalis virulence factor and is regulated by a 
quorum sensing mechanism that is dependent on the density of eukaryote cells. In the 
absence of target cells, cytolysin production is repressed by CylR1 that dimerizes and 
binds specifically to an inverted repeat that overlaps the -35 region of the cytolysin 
operon promoter (Figure 11a). However, a low-level of cytolysin peptides is ensured by 
basal transcription of the biosynthetic cluster. The two peptides form an insoluble 
complex that has neither regulatory nor cytolytic activity. In the presence of the target 
cells, CylLL will bind preferentially to phosphatidylcholine: cholesterol lipid bilayers 
and will no longer bind with CylLS. Thus, this peptide will accumulate in the 
extracellular environment and will lead to an increase in cytolysin expression level 
(Figure 11b). The mechanism of derepression is still not completely understood, but it is 
known that a second membrane binding protein, called CylR2, is also involved but with 
unknown function. Overall, it is clear that this mechanism allows E. faecalis to use a 
single peptide to probe the environment for cytolysin targets and induce its production 
only when it is needed, leading to an economy of regulation (Coburn, et al., 2004, 
Willey & Donk, 2007). 
 
Figure 11 – Regulation mechanism of cytolysin biosynthesis in the absence (a) and presence (b) of eukaryotic 
target cells (Willey & Donk, 2007). 
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1.1.4 Characterization of the lantibiotic lichenicidin 
Bacillus licheniformis I89 is a Gram positive endospore-forming bacterium found in 
the soil that produces a peptide with activity against Gram positive bacteria (Mendo, et 
al., 2004). Other microorganisms that also belong to this Bacillus group have been 
described as producers of proteases, amylases, antibiotics and surfactants, which are 
considered biotechnologically important compounds. Among these compounds 
produced there are antimicrobial peptides that can be nonribosomally or ribosomally 
synthesized (Caetano, et al., 2011).  
Considering the ribosomally synthesized peptides possessing antibacterial activity, it 
was found that B. licheniformis I89 naturally produces a two-component lantibiotic 
(class II): lichenicidin (Figure 12). 
 
 
Figure 12 – Representation of Bliα and Bliβ structures (Caetano, et al., 2011) 
Lichenicidin is active against MRSA and Listeria monocytogenes. Apparently, its 
mechanism of action involves the interaction of both peptides with the membrane 
molecule lipid II, leading to the formation of pores in the bacterial membrane in such a 
way that the targeted microorganism loses its viability (Shenkarev, et al., 2010). 
According to the definition of two-component lantibiotics, if only one of the peptides is 
produced, there will be no antimicrobial activity, but the activity can be restored if the 
complementary peptide is supplied by cross feeding (Caetano, et al., 2011).  
All the genes necessary for the lichenicidin synthesis, regulation and immunity are 
encoded in the lic gene cluster (Figure 13) (Rey, et al., 2004, Dischinger, et al., 2009, 
Caetano, et al., 2011). 
 
Figure 13 – Representation of the lic gene cluster organization, according to the genome annotation for Bacillus 
licheniformis ATCC 14760 (Caetano, et al., 2011). 
Since the original producer B. licheniformis I89 has low transformation efficiency, it 
was difficult to study the function of the genes present in the lic cluster. Thus, the 
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complete gene cluster for lichenicidin production was introduced in the Gram negative 
host Escherichia coli. In this heterologous system, lichenicidin production was achieved 
(Caetano, et al., 2011). Usually, E. coli is the host microorganism of choice to be used 
for heterologous expression due to its characteristics for genetic manipulations, 
handling, costs and generation time. The two lichenicidin peptides are encoded by two 
different structural genes (licA1 and licA2) that after their expression are modified by 
two different proteins LicM1 and LicM2, respectively. The peptides become 
biologically activate after the removal of the leader sequence and are transported to the 
extracellular environment by a single multifunctional protein called LicT that contains 
an ABC transporter and a protease domain (Caetano, et al., 2011). After all the post-
translational modifications, LicA1 and LicA2 became mature lantibiotics and are 
designated as Bliα and Bliβ (Figure 12), respectively. The lic biosynthetic cluster also 
includes other genes, for instance licP, which encodes a serine protease acting 
exclusively in the activation of Bliβ peptide. licR encodes a putative regulatory protein 
and licY encodes a protein with unknown function. In E. coli, LicR and LicY seem to be 
involved exclusively in the production of Bliα or Bliβ, respectively. licX encodes a 
small uncharacterized protein with unknown function that does not affect lichenicidin 
production in the heterologous expression host. licFGEHI are the so-called immunity 
genes, where licFGE encode an ABC transporter, licI encodes an individual immunity 
protein and licH encodes an auxiliary protein essential for the correct assembly of the 
functional ABC transporter. The presence of these genes is not essential for the 
lichenicidin production in E. coli (Caetano, et al., 2011, Caetano, et al., 2011). 
1.1.5 Bioengineering of lantibiotics 
The gene encoded nature of lantibiotics allowed the development of mutagenesis 
systems to produce novel structural variants. These systems can be used not only to 
reveal information about structure-function relationships but also to enhance chemical 
and antimicrobial properties of lantibiotics and even their rational design. Usually in 
vivo bioengineering of the structural peptide(s) is performed in the original producer or 
closely relatives once there are multiple genes required for lantibiotic synthesis and 
immunity (Kuipers, et al., 1996, Field, et al., 2007, Nagao, et al., 2007). 
Different techniques can be used to perform such modifications, namely site-directed 
mutagenesis and random mutagenesis. Site-directed mutagenesis ensures the 
replacement of a single specific amino acid but it is time consuming and unsuitable for 
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random mutagenesis approaches. Those strategies established/confirmed the importance 
of specific residues both in the structural peptides and respective leader sequences 
(Field, et al., 2007). Several lantibiotics have already been mutated by site-directed 
mutagenesis approaches, for instance nisin A, nisin Z, gallidermin, epidermin and Pep5 
(Kuipers, et al., 1996). Nukacin ISK-1 was also object of bioengineering studies but 
using other methodologies for the insertion of mutations (Nagao, et al., 2007). 
Random mutagenesis is a useful tool to generate optimized, non active or altered 
proteins due to the insertion of random alterations in the DNA that encodes the protein. 
It can generate a large number of variants, some of which will produce a desired effect 
in the protein (Nicholl, 2008, Minamoto, et al., 2012). This approach is advantageous 
when comparing to the alternative site-directed mutagenesis as prior knowledge of the 
functional importance of each residue is not necessary; in fact, this technique requires 
efficient screening methods than previous sequence information. For the same reason, it 
could be very difficult to associate the improved phenotype with the underlying 
genotype (Nicholl, 2008, Minamoto, et al., 2012, Zhang, et al., 2012). 
Several methods to perform random mutagenesis are known such as error-prone PCR 
(epPCR), UV irradiation or chemical mutagenesis and saturation mutagenesis. epPCR is 
the most widely used for in vitro mutagenesis and will be used in the present work. It is 
usually performed using DNA polymerases without proof-reading activity (Minamoto, 
et al., 2012). 
The mutation frequency is controlled by adjusting the initial amount of target DNA 
and/or the number of thermal cycles and can be determined for an amplification reaction 
considering the error rate of the DNA polymerase and the number of duplications 
during PCR (Emond, et al., 2008). The mutation frequency must be adapted to a 
particular application. For instance, to analyze protein structure-function relationships, 
the desired mutation frequency is one amino acid change (1–2 nucleotide changes) per 
gene (Vartanian, et al., 1996), whereas to obtain proteins with improved activities it is 
necessary to isolate them from highly mutagenized libraries, exhibiting 20 mutations 
per gene (Daugherty, et al., 2000). Mutant libraries can be constructed at various 
mutagenesis frequencies: low mutagenesis frequency offer a high probability of 
functional sequences and a low probability of beneficial mutations (increased activity) 
while high mutagenesis frequency leads to a high probability of lethal mutations with a 
high probability of unique sequences, that are more difficult to identify. Usually several 
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libraries are performed combining different mutation frequencies according to the 
intended results (Ye, et al., 2012). 
 
1.2 Objectives of this thesis 
The work developed in the present thesis has its main focus in the characterization of 
the regulation mechanism of lichenicidin biosynthesis and its heterologous expression 
under the control of E. coli determinants. Additionally a system of peptide 
bioengineering to produce mutants with significant altered bioactivity was attempted. 
To achieve these goals, several studies were conducted and constituted the following 
tasks: 
‒ Determine the role of LicR protein in lichenicidin biosynthesis 
regulation, using either the heterologous expression system in an E. coli host and 
the original producer, B. licheniformis I89. 
‒ Understand if the production of each lichenicidin peptides can be 
achieved independently, using only their own essential genes and under the 
control of an E. coli promoter. 
‒ Compare the yield of production and bioactivity of the different 
biosystems available for the production of lichenicidin in order to understand 
which of them is the most efficient. 
‒ Produce E. coli mutants with increased and decreased or no activity using 
a peptide bioengineering approach: random mutagenesis. 
  
 
 
 
 
 
CHAPTER II 
 
INVOLVEMENT OF LICR IN THE 
BIOSYNTHESIS OF BLIα PEPTIDE 
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2.1 Background 
Biosynthesis of lantibiotics is a process that requires a significant amount of energy 
and consequently it must be strictly controlled (Bierbaum & Sahl, 2009). The system 
generally involved in lantibiotic regulation is composed by two proteins: the receptor-
histidine kinase LanK and the transcriptional response regulator LanR. The first one is 
the responsible for monitoring external environmental signals, inducing a response 
cascade involving the phosphorylation of LanR that is intracellularly located. LanR will 
then mediate the final response, usually by changing gene expression (Dale & Park, 
2004). Regarding two-component lantibiotics biosynthesis regulation, the most studied 
case is cytolysin, as mentioned in the previous chapter (see section 1.1.3).  
The analysis of LicR sequence showed higher sequence homology with helix-turn-
helix (HTH) XRE family-like proteins (Figure 14), including the HalR protein (encoded 
in the two peptide lantibiotic haloduracin gene cluster) and also with other regulator 
proteins from strains belonging to the Bacillus genus. The HTH_XRE proteins are a 
family of DNA binding proteins, normally associated with the regulation of gene 
transcription (Wintjens & Rooman, 1996). 
 
 
Figure 14 - (A) Sequence of LicR protein with the predicted HTH motif highlighted (yellow). (B) LicR 
secondary structure according to the prediction of the (PS)2 Protein Structure Prediction Server (Chen, et al., 2006) 
In a previous study, using the heterologous host E. coli, it was observed that the 
deletion of licR gene from the lichenicidin gene cluster resulted in the absence of Bliα 
peptide (Caetano, et al., 2011). Thus, based on LicR sequence homology, it was 
hypothesized that LicR could be involved in the regulation of licA1 and/or licM1 
transcription, once these genes are directly implicated in the production of Bliα peptide 
but not in Bliβ’s. 
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To confirm this hypothesis, the objective of this chapter was to compare the licA1 
and licM1expression levels of the licR knockout mutant (E. coli BLic5∆R) with those of 
the control strain (E. coli BLic5 containing licR gene). As it will be explained, deletion 
of licR in the lichenicidin original producer B. licheniformis I89 was also attempted. 
 
2.2 Results and Discussion 
2.2.1 Analysis of the licA1M1 promoter region  
Taking in account that LicR as a putative regulatory protein and considering the fact 
that the deletion of licR in E. coli lead to the absence of Bliα peptide without affecting 
Bliβ, it seemed reasonable to assume that LicR should be involved in the regulation of 
licA1 and/or licM1 expression. 
The licA1M1 nucleotide region was characterized regarding the presence of putative 
promoters, ribosome-binding sites (RBS) and terminators (Figure 15). As shown in the 
figure, it was possible to identify a promoter upstream to the licA1 gene, containing 
both -35 and -10 boxes (PlicA1 promoter). However, such a genetic structure could not be 
identified into the intergenic region between licA1 and licM1. Also two putative RBS 
were identified upstream of these two genes. Moreover, the search for terminators 
within the sequence was performed using the web server Transcriptional Terminators 
Prediction. Only results presenting the same orientation of both genes were considered 
and only the first one after the stop codon of the coding sequence. Considering all these 
restrictions, two terminators within the sequence were found: one after licA1 coding 
sequence and another after licM1. Both seem to be Rho-independent termination 
signals, since they present an inverted repeat sequence GC-rich followed by four or 
more adenines. During transcription, the inverted repeat sequence allows RNA to form a 
stem-loop structure that causes the release of the RNA from DNA polymerase, which 
stops the transcription. 
In conclusion, this analysis suggests that licA1 and licM1 expression should be under 
the control of the PlicA1 promoter. Thus, licA1 and licM1 are transcribed together. 
Nevertheless one putative terminator was identified after each of these genes, thus 
emphasizing the importance of studying the expression levels of licA1 and licM1 
independently. 
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Figure 15 – Representation of lichenicidin gene cluster region containing licA2, licA1 and licM1 genes. (A) 
Region prior to licA1; (B) Intergenic region between licA1 and licM1; (C) terminators according to Transcription 
Terminator Prediction web server; -35 and -10 (Pribnow box) – transcription regulatory regions; the arrow marks the 
trascription initiation site (according to BPROM software); RBS – ribosome binding site. 
 
2.2.2 Analysis of total RNA extracted from BLic5 and BLic5ΔR strains 
The expression levels of licA1 and licM1 genes in the presence and absence of the 
putative transcriptional regulator licR was predicted to be performed using RT-qPCR. 
After extraction of total RNA from BLic5 and BLic5∆R strains, the possible 
contamination with DNA was evaluated by PCR. In the reactions, primers targeting the 
licA1 and licM1 complete genes were used. Also, two positive controls, consisting of 
colonies of BLic5 and BLic5∆R strains, were always included. It was observed that the 
extraction procedure was efficient regarding the absence of total DNA, since none of the 
two genes were amplified when total RNA was used as template. As expected, 
amplification was always observed for licA1 and licM1 genes for the positive controls. 
However, the analysis of the agarose gel revealed a difference in the licM1 
amplification: the amplicon of BLic5∆R presented higher molecular weight than that of 
BLic5 (Figure 16). 
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Figure 16 – Electrophoresis gel representing the licM1 amplification of 
total RNA (lines 1 and 2) and the positive controls (lines 3 and 4); M – 
LadderMix GeneRuler; 1 – BLic5 total RNA; 2 – BLic5∆R total RNA; 3 – 
BLic5 colony; 4 – BLic5∆R colony 
 
 
Subsequently, the same reaction was performed including also a colony of the 
original lichenicidin producer B. licheniformis I89 strain, which allowed concluding that 
licM1 amplification for BLic5 and I89 strain presented the same molecular weight (data 
not shown). So, the size of fragment obtained for BLic5∆R was bigger that the 
expected. This result suggested that licM1 gene should possess an insertion in the licR 
knockout strain. Therefore, the RT-qPCR analysis was not performed and a new 
BLic5∆R knockout strain was constructed. 
 
2.2.3 Comparison of lichenicidin production between BLic5 and BLic5ΔR 
strains  
To obtain a new BLic5ΔR knockout strain, the licR gene was deleted from the pLic5 
fosmid according with the procedure described in section 2.4.3. The obtained fosmid 
(pLic5ΔR) was investigated for the correct licM1 amplification. Since an amplicon of 
the same size as licM1 was obtained with I89 strain total DNA and with pLic5ΔR DNA, 
the fosmid was transformed in E. coli BL21-Gold(DE3) resulting in the correct 
BLic5ΔR strain.  
The production of lichenicidin peptides by BLic5ΔR was first evaluated by colony 
bioassay. The plates showed that BLic5ΔR strain was able to produce both lichenicidin 
peptides, since an inhibition area against M. luteus was observed (Figure 17). This result 
demonstrated that in the heterologous expression system previously described by 
Caetano et al. (2011) licR is not essential for Bliα production. Thus, the results 
previously obtained were due to LicM1 inactivity, instead of the licR absence.  
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Figure 17 – Antibacterial activity exhibited by BLic5 and the new BLic5∆R strains. 
 
The colony-bioassay indicated that both Bliα and Bliβ were produced by BLic5ΔR 
strain. However, using this technique, a comparison of the production levels with that of 
the control strain (BLic5) is not possible. Thus, to investigate the impact of licR absence 
on lichenicidin production levels, liquid cultures of both strains were performed in 
triplicate and the lantibiotic was extracted with 1-butanol. After evaporation, the 
bioactivity of the samples was investigated and quantified using arbitrary units (section 
3.5.3). The same extracts were analyzed by HPLC-ESI-MS to detect and measure more 
accurately the amounts of Bliα and Bliβ present.  
The bioactivity results showed that there were no significant differences between 
both strains (Figure 18) since the absence of activity was observed approximately at the 
same dilution for BLic5 and BLic5ΔR. This could indicate that licR has no influence in 
the lichenicidin biosynthesis process, when the lic gene cluster is expressed in E. coli. 
 
 
Figure 18 - Quantification of BLic5 and BLic5ΔR bioactivity against M. luteus.  The AU/mL was calculated 
using a series of dilutions and considering the last well that showed inhibition. 
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However, these results were compared and confirmed by the HPLC-ESI-MS 
analysis. Using this technique, the concentration of both lichenicidin peptides was 
determined (Figure 19). 
 
 
Figure 19 – Quantification of Bliα and Bliβ in production both BLic5 and BLic5∆R by HPLC-ESI-MS. 
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directly; if the lactone concentration is sufficient, the activated regulatory protein will 
switch on the target genes (Dale & Park, 2004) .  
Thus, the results obtained for licR when E. coli was used as the host organism where 
not similar to those obtained when the lichenicidin natural producer was employed. 
Therefore, the same tests were attempted using B. licheniformis I89 strain.  
 
2.2.4 licR deletion in B. licheniformis I89  
Considering the differences of the regulatory mechanisms between Gram positive 
and Gram negative organisms, licR was deleted in the original lichenicidin producer. To 
achieve this, a shuttle vector (Bacillus and E. coli) containing an apramycin resistance 
cassette flanked by approximately 30 bp of licR 5’ and 3’-ends, was constructed. The 
plasmid pKSV7 that encodes the resistance to ampicilin in E. coli and includes a 
replication origin that is sensitive to temperature in Bacillus (propagation temperature: 
30
o
C; non-replication temperature: 42
o
C) was used. The shuttle vector constructed was 
pKlicR:Apra and it was used for all the transformations performed.  
The transformation of B. licheniformis is a difficult step regarding the genetic 
manipulation of this species (Rey, et al., 2004). Thus, several procedures to obtain B. 
licheniformis I89 transformants where attempted in the present study, including 
transconjugation, electroporation and protoplast transformation (see section 2.4.6). The 
same plasmid was used in all the different procedures but on the electroporation 
protocol the solution containing this vector was previously desalted, as salts can 
interfere with the electric pulse. The B. licheniformis MW3 strain was used as a control. 
In this strain, the genes encoding type I restriction enzymes were deleted, and the 
transformation efficiency rates were increased (Hoffmann, et al., 2010).  
Despite all the protocols tested, it was not possible to obtain a B. licheniformis I89 
transformant. Consequently, it was not possible to investigate the influence of licR in 
the lichenicidin biosynthesis in the natural producer. 
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2.3 Conclusions 
LicR has homology with several regulatory proteins, mainly those of the HTH_XRE 
superfamily, which are known to have regulatory functions in many microorganisms. 
Taking that in account and considering the fact that the first knockout in E. coli did not 
produce Bliα, it was assumed that LicR was a regulatory protein, controlling Bliα 
biosynthesis. However, herein, it was shown that inhibition of activity was due to an 
insertion within the licM1 gene, leading to an incorrect processing of the final α-peptide. 
Thus, in this study it was found that the absence of LicR does not abolish Bliα 
production in E. coli. Also, the bioactivity results suggested that the production levels 
were also not affected. Contrarily to what was observed in the bioassay, spectrometry 
analysis indicated that in BLic5∆R strain lichenicidin yields are higher when compared 
with the control BLic5 strain. 
Though, considering that the regulation mechanisms of E. coli (Gram negative) are 
significantly different from those of the original producer B. licheniformis I89 (Gram 
positive), the same study was attempted in the original lichenicidin producer strain. 
Despite the several efforts, it was not possible to transform B. licheniformis I89 strain. 
Consequently, licR knockout strain could not be obtained so far. 
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2.4 Experimental Procedures 
2.4.1 Bacterial strains and cultivation media 
The characteristics of the E. coli strains containing the lichenicidin cluster and used 
in this section are presented in Table 1. These strains were maintained in Luria-Bertani 
agar (LA; Merck) plates or grown in Luria-Bertani broth (LB; Merck) at the 
appropriated temperature. Liquid cultures were performed using medium M containing 
10 g/L of NaCl, 10 g/L of tryptone, 5 g/L of yeast extract, 10 g/L of KH2PO4, with a 
final pH of 6.5, adjusted with NaOH (Mendo, et al., 2004). B. licheniformis I89 was 
first isolated from a hot spring in Azores island (Mendo, et al., 2000). Micrococcus 
luteus ATCC 9341 was used as the indicator strain in the bioassay to evaluate 
lichenicidin production. These two Gram positive strains were maintained routinely in 
tryptic soy agar (TSA; Merck). 
Table 1 – Description of the E. coli strains used in this section. 
Strain Description Phenotype Reference 
BLic5 
E. coli BL21-Gold(DE3) containing the pLic5 
fosmid (entire lic biosynthetic cluster) 
Clo
R 
(Caetano, et 
al., 2011) 
BLic5ΔR 
E. coli BL21-Gold(DE3) containing the pLic5ΔR  
fosmid (pLic5 with licR gene deleted) 
Clo
R
 
pKD20/pLic5 
E. coli BW25113 Containing the pKD20 (oriTS) 
plasmid and the pLic5 fosmid  
Amp
R
 Clo
R
 
S17-1 E. coli S17-1 – 
(Richhardt, 
et al., 2010) 
ET12567 E. coli ET12567 containing the pUZ8002 plasmid Kan
R
 Clo
R
 
(Macneil, et 
al., 1992) 
S17pKlicR:apra E. coli S17-1 transformed with pKlicR:apra Clo
R
 Amp
R
 Apra
R
  This study 
ETpKlicR:apra E. coli ET12567 transformed with pKlicR:apra Kan
R
 Amp
R
 Apra
R
  This study 
 
2.4.2 Total RNA extraction 
Total RNA from E. coli BLic5 and BLic5∆R strains was purified using the Trizol 
Max Bacterial Isolation Kit (Invitrogen). The procedure was divided in 3 steps (sample 
homogenization, phase separation and precipitation of RNA), followed by DNase 
treatment using Turbo DNA-free kit (Ambion). 
 
2.4.2.1 Sample homogenization 
The bacterial strains were cultivated in medium M containing 12.5 µl/mL of Clo with 
aeration (180 rpm) at 37 
o
C, until an OD600nm of 0.4-0.6. 1.5 mL of this culture was 
transferred to a pre-chilled microcentrifuge tube and centrifuged at 6000 xg for 5 min at 
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4 
o
C. The supernatant was discarded, the cell pellet resuspended in 200 µl of preheated 
(95 
o
C) Max Bacterial Enhancement Reagent and incubated at 95
o
C for 4 min. 1 mL of 
TRIzol
®
 Reagent was added to the lysate and the mixture was incubated at room 
temperature for 5 min. 
 
2.4.2.2 Phase separation 
To the previously obtained lysate 200 µL of cold chloroform were added and the 
mixture was vigorously shaken by hand for 15 s, incubated at room temperature for 3 
min, and then centrifuged at 12 000 xg for 15 min at 4 
o
C. After centrifugation, three 
phases were formed: the lower red phenol-chloroform phase, an interphase and a 
colorless aqueous phase containing RNA (approximately 400 µl). 
 
2.4.2.3 RNA precipitation 
The upper phase containing the RNA was transferred to a new tube, 500 µL of cold 
isopropanol was added and incubated at room temperature for 10 min, to precipitate 
RNA. The mixture was centrifuged at 15 000 xg for 10 min at 4 
o
C and the supernatant 
carefully removed. The pellet was washed with 1 mL of 75% ethanol and centrifuged at 
7500 xg for 5 min at 4 
o
C. Finally, the pelleted RNA was air-dried and resuspended in 
50 µL of RNase-free water, followed by incubation for 10 min at 60 
o
C. 
2.4.2.4 DNase treatment 
The contamination of the extracted total RNA with DNA was avoided by treatment 
with DNase using the Turbo DNA-free kit (Ambion), according with the manufacturer’s 
instructions. Briefly, 5 µL of Turbo DNase buffer and 1 µL Turbo DNase (2U/µl) was 
added to 50 µL of total RNA. The reaction was carefully mixed and incubated at 37 
o
C 
for 45 min. After incubation, 5.5 µL of DNase Inactivation Reagent was added and the 
mixture was incubated at room temperature for 2 min. Finally, the reaction was 
centrifuged at 10 000 xg for 1.5 min and the supernatant containing the RNA was 
transferred to a new microcentrifuge tube and stored at -80 
o
C. 
 
2.4.2.5 Analysis of RNA integrity and concentration 
In order to check for RNA integrity, 2 µL of RNA solution were run in an 
electrophoresis gel 1% agarose. To perform this, electrophoresis new buffer was used. 
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RNA concentration was determined using Qubit fluorimeter using Quant-iT
TM
 RNA 
reagents according to manufacturer’s instructions, as described in Appendix 11. 
 
2.4.3 Amplification of licA1 and licM1 genes 
Despite the previous described verification of DNA contamination, a more specific 
test was performed, to check for the amplification of the target genes, licA1 and licM1. 
For that, both genes were amplified using the total RNA extracted from both BLic5 and 
BLic5∆R strains. Colonies of those strains and B. licheniformis I89 were used as 
positive controls. The primers used for those amplifications are listed on Table 2: 
Table 2 – List of primers used to amplify licA1 and licM1 and respective sequences and annealing temperatures. 
The expected size of each amplicon and the extension time for each target gene are also indicated. 
Primer name Primer sequence (5’→3’) 
Annealing 
temperature (
o
C) 
Expected 
amplicon (bp) 
Extension 
time 
Comp_licA1 Fw AGGTGGGATCCATGTCAAAAAAGGAAATG 
50 250 45 s 
Comp_licA1 Rv CCCGCCTCGAGAACTTAGTTACAGCTTGGC 
Comp_licM1 Fw AGGTCGGATCCATGAATGAAAAATCC 
52 3181 3 min 
Comp_licM1 Rv CATAGATTCTCGAGTTAAAACACGTTTTC 
 
The amplification reaction was performed with Taq DNA polymerase (Promega) as 
described in Appendix 8 using the annealing temperatures indicated in Table 2. PCR 
products were separated by electrophoresis 1% agarose gel to check for possible 
contaminations on total RNA reactions. 
2.4.4 Production of licR knockout mutant 
2.4.4.1 Amplification of the disruption cassette 
In order to perform the new licR knockout mutant in the pLic5 fosmid, an apramycin 
disruption cassette was amplified using primers binding to the flanking regions of the 
licR gene.  
The plasmid pIJ733 was used as template and was extracted as described in 
Appendix 6. The amplification reaction containing 50 ng of template DNA, 0.5 µL of 
dNTP’s (100 mM), 10 µL of Herculase buffer (5X), 0.5 µL of each primer (100 pmol/ 
µL), 2 µL of DMSO and 1 µL of Herculase II enzyme (5U/ µL), in a final volume of 50 
µL. The primers used are listed on Table 3: 
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Table 3 – Primers used to amplify the disruption cassette licR:Apra from pIJ733 
 
The amplification program was as follows: 94 ºC for 2 min, 10 cycles with 
denaturation at 94 ºC for 45 sec, annealing at 50 ºC for 45 sec and extension at 72 ºC for 
90 sec, 15 cycles with denaturation at 94 ºC for 45 sec, annealing at 55 ºC for 45 sec and 
extension at 72 ºC for 90 sec and a final extension at 72 ºC for 5 min.  
2.4.4.2 Transformation of E. coli BW25113/pKD20/pLic5 with the disruption 
cassette 
The licR disruption cassette was used to transform E. coli BW25113/pKD20 cells, 
containing the pLic5 fosmid. The procedure was performed as follows: a pre-culture of 
this strain was prepared in LB medium containing 100 μg/mL of Amp and 12.5 μg/mL 
of Clo antibiotics and it was growth at 30 ºC. 100 μL of the culture was used to 
inoculate 10 mL of fresh LB medium containing the same concentration of the selective 
markers, 20 mM of MgSO4 and 10 mM of L-arabinose (Sigma). The cells were grown 
at 30 ºC at 160 rpm until an OD600 of approximately 0.4 (between 3 to 4 hours). The 
cells were collected by centrifugation at 6000 xg for 5 min at 4 ºC and washed with 10 
mL of ice cold 10 % glycerol. This procedure was repeated once and the cells were 
finally resuspended on 100 μL of the same solution. For transformation, 50 μL of the 
prepared cells were mixed with 100-150 ng of the licR disruption cassette. The cells 
were subject to electroporation and the transformants were selected on LA plates 
containing 50 μg/mL of Apra and 12.5 μg/mL of Clo, grown at 37 ºC. The substitution 
licR gene by the Apra
R
 cassette was confirmed by colony PCR.  
 
2.4.4.3 Elimination of ApraR cassette 
One positive clone was selected and grown overnight at 37 ºC in LB containing 50 
μg/mL of Apra and 12.5 μg/mL of Clo, in order to extract the pLic5ΔR:Apra fosmid. 
The fosmid was extracted by alkaline lysis as described in Appendix 7. The fosmid was 
disgested with the restriction enzyme BmtI (New England Biolabs) in a final volume of 
80 μL, containing 1-3 μg of fosmid DNA, 1X of NEBuffer 2 and 20 U of enzyme. The 
mixture was incubated at 37 ºC for 3 hours. Subsequently, sterile distilled water as 
Primer Primer sequence (5’→3’) 
lanR_Fw TTTTTGTTATAAACTCTTTACAATGTGTAAAAAACATTGGCTAGCTGTAGGCTGGAGCTGCTTC 
lanR_Rv TCCTTCTCAAATAACGCGGCAATGCGAAACCCCATTAACGCTAGCATTCCGGGGATCCGTCGACC 
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added to the digestion for a final volume of 600 μL. This mixture was extracted once 
with phenol/CIA (Invitrogen) and DNA was precipitated with 1/10 vol of potassium 
acetate (3 M, pH 5.5) and 0.6 volume of isopropanol. The mixture was incubated at 
room temperature for 15 min and centrifuged at 4 ºC, 12000 xg for other 15 min. The 
pelleted DNA was washed with 100 μL of 70 % ethanol and completely dried for 15 
min in the flow chamber. The final elution was performed in 10 μL of sterile distilled 
water. The complete digestion of the fosmid was confirmed by gel electrophoresis 
analysis, loading 1 μL of the digested DNA. The religation of the BmtI-digested fosmid 
was performed in a total volume of 50 μL containing approximately 1-2 μg of DNA, 1X 
ligase buffer and 10 U of T4 DNA ligase (Fermentas). The reaction was incubated at 20 
ºC for 15 min and 5 μL of this ligation was use to transform chemically competent E. 
coli BL21-Gold(DE3) cells. The transformants were selected on LB agar plates 
containing 12.5 μg/mL of Clo. The obtained colonies were further cultured on plates 
containing 12.5 μg/mL of Clo and 50 μg/mL of Apra. The clones presenting the 
phenotype Clo
R
Apra
S
 were selected as those containing the licR gene deletion without 
the Apra
R
 cassette. The absence of this cassette was further confirmed by colony-PCR. 
The integrity of licM1 gene was also confirmed by colony-PCR as described in section 
2.4.3.  
2.4.5 Construction of plasmid for licR disruption in Bacillus 
2.4.5.1 Insertion of licR:Apra cassette into pKSV7 vector 
In order to obtain a Bacillus licheniformis I89 licR mutant, it was necessary to 
construct a plasmid containing a licR disruption cassette that was able to replicate in 
Bacillus. To achieve this, the plasmid pKSV7 was used as vector (Li & Kathariou, 
2003). This plasmid contains an origin of replication for Bacillus sensitive to the 
temperature (permissive temperature 30 ºC), an E. coli origin of replication, a cat gene 
conferring resistance to chloramphenicol and the pUC19 multiple cloning site. This 
plasmid was extracted using the QIAprep Spin MiniPrep Kit (QIAGEN), according 
with manufacturer’s instructions. Approximately 600 ng of pKSV7 vector was digested 
with 10 U of SmaI restriction enzyme (Fermentas) in a reaction with a final volume of 
40 μL, containing 1X Tango buffer. The reaction was incubated at 30 oC for 1 hour. 
SmaI digestion will generate blunt ends, meaning that the licR:Apra
R
 disruption cassette 
amplified in section 2.4.4.1 can be directly used to perform a blunt-end ligation. 
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After digestion, the plasmid was purified using the JETquick Purification kit 
(Genomed) as described in Appendix 10 and its concentration was determined using 
Qubit
®
 (Appendix 11).  The ligation reaction was performed in a final volume of 20 μL, 
containing: 50 ng of SmaI digested pKSV7, 250 ng of licR:Apra
R
 cassette, 1x of T4 
DNA ligase buffer, 5U of T4 DNA ligase and 2 µL of 50 % PEG 4000 solution. The 
reaction was incubated at 22 
o
C for 1 h and then stored at -20
o
C until further use. 
2.4.5.2 Transformation 
To ensure the integrity and functionality of the pKlicR:Apra, a subcloning procedure 
was carried out using chemically competent E. coli DH5α cells. 5 µL of the ligation 
were used for transformation procedure and the transformation was performed by heat 
shock as described in the Appendix 4. Transformants were selected overnight at 37 
o
C 
on LA plates containing 100 µg/mL of Amp and 50 µg/mL of Apra. 
Positive clones were selected using colony-PCR with the appropriate primers using 
the protocol described in Appendix 8 using lanR primers (Table 3). One of the positive 
clones was isolated in a new LA plate containing the same selective markers and used to 
extract the pKlicR:Apra plasmid with the alkaline lysis procedure described in 
Appendix 7.  
After extraction, the plasmid was treated with RNase at a final concentration of 2 
mg/mL during 1 hour at 37 
o
C. Then, 1 volume of Phenol/CIA was added to remove 
proteins and shaken. The solution was centrifuged in a top-table centrifuge at top speed 
for 5 min and the upper organic phase was collected to a clean 1.5 mL microcentrifuge 
tube. 1/10 volume of NaAc and 0.6 volume of isopropanol were added and the 
suspension was left for 10 min on the table to let precipitation to occur. A new 
centrifugation was performed at 4 
o
C, top speed for 15 min. the supernatant was 
discarded and the plasmid DNA was resuspended in 500 µL of 70 % ethanol. The 
suspension was centrifuged as mentioned and the supernatant was discarded. The pellet 
was air-dried to remove residual ethanol and then resuspended in 200 µL of distilled 
water. 
2.4.6 B. licheniformis transformation 
In order to produce a knockout strain of B. licheniformis diverse protocols described 
for Bacillus transformation were tested and improved, including transconjugation, 
electroporation and protoplasts transformation. 
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2.4.6.1 Transconjugation using E. coli strains 
The transconjugation protocol applied in this study was adapted from Richhardt et al 
(Richhardt, et al., 2010). The procedure was tested using two different donor strains: the 
E. coli S17-1 and the E. coli ET12567. The first strain is able to methylate DNA and the 
other is not able to methylate it. This could allow to understand if DNA methylation 
could influence the intake of pDNA by I89 strain. Thus, chemically competent cells 
were prepared for both E. coli strains and transformed with pKlicR:Apra using heat 
shock protocol (Appendix 4). 
In general terms, B. licheniformis and the two E. coli strains containing the 
pKlicR:Apra plasmid were inoculated in 5 mL of LB medium with the appropriate 
selective markers (see Table 1). The cultures were grown overnight at 37 
o
C. Then, 50 
mL of LB were inoculated with 1 mL of Bacillus culture and 50 mL of LB with the 
appropriate antibiotics were inoculated with 1 ml of each one of the overnight cultures 
and allowed to grow until the OD600 reached 0.6-0.8. Each culture was centrifuged at 4 
o
C for 15 min at 3200 xg and the cell pellets resuspended in 15 mL of holding buffer 
(12.5 mM KH2PO4, 12.5 mM K2HPO4, 1 mM MgSO4, pH 7.2). These two steps were 
repeated twice and the last resuspension was performed in 30 ml of holding buffer. At 
this stage, the cells were prepared for transconjugation by direct contact and also using 
filter matting. Also, the influence of B. licheniformis I89 incubation at 49 
o
C before the 
transconjugation procedure described by Richhardt, et al. (2010) was tested.  
Briefly, 10 mL of B. licheniformis I89 culture (either with or without 49 ºC 
treatment) was mixed with 5 mL of each one of the E. coli donor strain (2:1). 
Afterwards, two distinct approaches were adopted: 
a) Direct contact: 1 mL of the bacterial mixture was spread in LA plates in duplicates 
and one plate was incubated at 30 ºC and other plate at 37 ºC for 24 h. Following this, 
each plate was washed with 1 mL of LB medium. 
b) Filter matting: 3 mL of the bacterial mixture was filtered with 0.45 μm 
nitrocellulose filters. This was performed in duplicates and each one of the filters was 
placed on a LA plate with the cells forming the top layer. One plate was incubated at 30 
ºC and other plate at 37 ºC for 24 h. Following this, each filter was transferred to a 2 mL 
microcentrifuge tube containing 900 µL of LB medium and mixed.  
For both procedures, the volume of bacterial suspension obtained was divided in two 
1.5 mL microcentrifuge tubes (approximately 450 µL in each). One of the tubes was 
treated at 80 
o
C for 20 min, in order to select B. licheniformis I89 spores. After this, 
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both tubes were centrifuged at 6000 xg for 2 min and the most of the supernatant was 
discarded. The resulting pellet was resuspended in the remaining supernatant 
(approximately 100 μL) and plated in LB agar plates containing the appropriate 
antibiotics (12.5 μg/mL of Clo and 50 μg/mL of Apra). All the plates were incubated for 
24 h at 30 ºC. 
 
2.4.6.2 Electroporation 
Electroporation is a simple and rather efficient method to transform bacterial strains. 
However, it is known that B. licheniformis strains are among the most difficult 
transformable strains. Thus, electroporation was tested to transform B. licheniformis I89 
strain, using a protocol adapted from Tamagnini, et al (Tamagnini, et al., 2008). 
 A pre-culture of I89 was performed using 5 mL of LB containing 0.5 M of sorbitol 
and grown at 37 
o
C with aeration (180 rpm), overnight. The culture was diluted 20-fold 
in the same medium and grown at 37 
o
C with 250 rpm until an OD600nm of 1-1.1 was 
reached. Afterwards, it was centrifuged at 4 
o
C at 5000 xg for 5 min and the resulting 
pellets were washed twice with ice-cold electroporation solution (0.5 M sorbitol, 0.5 M 
mannitol and 10% glycerol). Finally, the pellet was resuspended in 1/40 volume of the 
same solution. For electroporation, 60 µL of the prepared electrocompetent cells were 
mixed with 50 ng of pKlicR:Apra. The pKlicR:Apra vector was previously desalted 
using a desalting membrane (Millipore) placed at the surface of a plate containing 
distilled water, for 15 min and transferred to a new tube. The electroporation was 
performed using 1 mm gap electroporation cuvettes (Bio-Rad) and a single electric 
pulse was given at 2.1 kV in the MicroPulser Electroporator (Bio-Rad). After pulse, 1 
mL of LB medium containing 0.5 M of sorbitol and 0.38 M of mannitol was 
immediately added and the suspension was incubated at 30 
o
C at 150 rpm for 3 h in a 15 
ml tube. The culture was finally plated onto LB agar medium with the appropriate 
selective markers (50 µg/mL of Apra) and incubated for 3 days at 30 
o
C. The plates 
were routinely monitored. 
 
2.4.6.3 Transformation of protoplasts 
Transformation of protocol is one of the most used procedures to transform Bacillus 
and other hardly transformable strains. The protocol applied in this study, was adapted 
from Horn and Waschkau, et al (Horn, 1990, Waschkau, et al., 2008) and included 
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some modifications kindly suggested by Dr. Claudia Borgmeier (AK Prof. Dr. F. 
Meinhardt, WWU Münster Institut für molekulare Mikrobiologie und Biotechnologie). 
30 mL of #416 medium were inoculated with a single colony using a 250 mL flask 
and grown overnight at 37 
o
C and 250 rpm. The overnight culture was diluted to an to 
an OD600nm of 0.1 in 100 mL of #416 medium and incubated at 37 
o
C, 250 rpm until the 
0.4-0.5 in the following ones. The culture was then transferred to a 50 mL sterile falcon 
tube and centrifuged at 4 
o
C at maximum rotation speed for 15 min. The pellet was 
resuspended in 5 mL of SMMP supplemented with 130 µL of freshly prepared 
lysozyme. The mixture was incubated at 37 
o
C with 90 rpm during approximately 30 
min. 20 mL of SMMP were added and gently mixed, followed by a centrifugation at 
2200 xg as mentioned for 10 min. The remaining pellet was resuspended in 5 ml of 
SMMP followed by a short heat step at 65 
o
C for 5 min to inactivate restrictases. The 
suspension was centrifuged at 1400 xg for 8 min at room temperature and 1 mL of 
SMMP/BSA were added to the cell pellet.  
25 µL of pKlicR:Apra DNA (100 ng/µL) was mixed with 25 µL of 2x SMM in a 
sterile 1.5 microcentrifuge tube. 500 µL of the prepared protoplasts was transferred to 
the tube containing the pDNA. 1.6 mL of 40 % PEG 8000 (prepared with 1x SMM) was 
placed in a 50 mL falcon tube and the mixture of protoplasts-plasmid was then 
transferred to this tube. The solution was gently shaken during 2 min at room 
temperature and of 5 mL of SMMP+ was added. The protoplasts were recovered by 
centrifugation at 8 
o
C at 500 xg during 8 min and finally resuspended in 1 mL of 
SMMP+. The suspension was incubated during 2h at 37 
o
C, 130 rpm standing angled. 
After incubation, the protoplasts were plated on DM3 agar supplemented with the 
appropriate selective marker (12.5 µg/mL of Clo and 50 µg/mL of Apra) and in DM3 
without antibiotics in order to estimate the number of regenerated protoplasts. Also, 
serial dilutions were performed (10
-2
/10
-5
) and plated on LB agar in order to obtain the 
number of non-protoplasted cells. Air bubbles must be avoided when doing the plates. 
The plates were incubated during 2-5 days at 37 
o
C. 
 
Solutions: 
#416 medium: per 1 l – 20 g of peptone, 10 g of yeast extract, 10 g NaCl, 100 mL 2 M sucrose (freshly added). 
SMMP medium: Mix equal volume of 2x SMM and 4x PAB. 
2x SMM: 1 M sucrose, 0.04 M sodium maleate and 0.04 M MgCl2.6H2O. Sterilize in the autoclave for 10 min. 
0.2 N sodium maleate: per 250 ml – 5.8 g maleic acid in 50 mL of 1N NaOH. Add sterile water until the desired 
volume. 
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4xPAB: per 1 l – 6 g beef extract, 6 g yeast extract, 20 g peptone, 4 g dextrose, 14 g NaCl, 14.72 g K2HPO4, 
5.28g KH2PO4 
SMMP+ medium: 100 mL of SMMP with 0.2 mL of 20 % BSA (filter sterilized) 
Lysozyme solution: 10 mg/mL in 1x SMMP (filter sterilized; freshly prepared) 
40 % PEG (w/v): 10 g PEG 8000 in 25 mL of 1x SMM. Sterilize in the autoclave for 10 min. 
DM3 regeneration agar/succinate based regeneration agar: 200 mL of 4 % agar (Cf=0.8 %), 500 mL of 1 M 
sodium succinate (acid succinic) pH 7.3 (Cf=0.5 M), 100 mL 5 % casaminoacids (Cf=0.5 %), 50 mL 10 % yeast 
extract (Cf=0.5 %), 100 mL 3.5 % K2HPO4, 1.5 % KH2PO4 (Cf=0.35 %, 0.15 %), 15 mL 40 % glucose (Cf=0.6 %), 
20 mL 1 M MgCl2 (Cf=0.02 M), 10 mL of sterilized dH2O, 5 mL of 20 % BSA (added to the mixture at 
approximately 55oC; Cf=0.1 %). 
 
2.4.7 Bioassay 
2.4.7.1 Preparation of extracts 
Bacterial strains were cultivated in 5 mL of medium M supplemented with the 
appropriated selective marker, at 37 
o
C, 180 rpm and overnight. 300 µl of this culture 
was used to inoculate 30 mL of medium M and incubated for 24 h at 37 
o
C, 180 rpm. 
This procedure was performed in triplicates for each strain. Afterwards, 5 mL of 1-
butanol (Merck) were added to 20 mL of the bacterial culture and shaken for 1 h. The 
mixture was centrifuged for 1 min at 6000 xg. 2 ml of the organic upper phase were 
collected and divided into two 1.5 mL microcentrifuge tubes. The organic solvent was 
evaporated at 50 
o
C for 3 hours using a SpeedVac evaporator (Labconco). For each 
replica, one pellet was stored at -80 ºC and sent for HPLC-ESI-MS/MS analysis. The 
other pellet was dissolved in 500 µL of 70% ACN:water and used for bioactivity 
quantification. For each replica, one tube was used to perform bioassays and the other 
one was sent to HPLC-ESI-MS/MS. 
 
2.4.7.2 Quantification by bioassay 
Twofold serial dilutions of the extracts were performed for each replica and 50 µL of 
each dilution were dispensed into wells previously made in the bioassay agar plates, 
containing the indicator strain M. luteus. After overnight incubation at 37 
o
C the 
inhibition halos were analyzed. 
The peptide activity was expressed as arbitrary units (AU). The arbitrary units per 
milliliter (AU/ml) were calculated using the reciprocal of the last dilution that gave a 
distinct zone of inhibition multiplied by the conversion factor (Ryan, et al., 1996). 
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3.1 Background 
One of the major advantages of using the E. coli system for heterologous expression 
is that this Gram negative bacteria is very amenable to genetic manipulation. 
The lichenicidin heterologous expression system in E. coli was firstly used to 
produce both α and β peptides in the same strain. In this system, the entire lichenicidin 
gene cluster was located on a fosmid, where the all the genes expressed are regulated by 
B. licheniformis determinants. However the production of both peptides simultaneously 
is not advantageous concerning downstream processing; so it was attempted to produce 
strains capable of synthesizing each peptide independently. For that, two strategies have 
already been developed: 
‒ Deletion of licA1 (to produce only Bliβ) or licA2 (to produce only Bliα) gene 
from the fosmid pLic5 (Caetano, et al., 2011). In these cases, the biosynthesis is still 
controlled by B. licheniformis determinants. 
‒ Deletion of licA1 and licA2 from pLic5 fosmid and transcomplementation with 
the respective gene into pET-24a(+) or pUC19a vectors (Caetano, et al., 2011, Cruzeiro, 
2012). In these cases only the expression of the structural genes is under the control of 
E. coli genetic determinants. The major advantage of this system is the easier 
manipulation of the structural gene allowing the attainment of variants of those genes. 
All of these systems involve the presence of the complete lic biosynthetic cluster 
inserted into a fosmid (approximately 25 Kb). Due to its high molecular weight, this 
structure can be instable. Also, the presence of the complete cluster can require more 
energy, so it could be advantageous to have two different strains producing each single 
peptide, since less energy would be necessary to express the genes involved and 
possibly making the process faster and more efficient. Thus, the production of Bliα and 
Bliβ separately in E. coli was attempted, using a construct of lower molecular weight. 
To achieve this, it was decided to clone only the genes necessary for Bliα (licA1, licM1 
and licT) or Bliβ (licA2, licM2, licT and licP) production into a plasmid. The plasmids 
were inserted into E. coli BL21-Gold(DE3) host and the production of the peptides was 
investigated by colony bioassay using E. coli strains producing the complementary 
peptide. Moreover, the levels of lichenicidin production for each system available were 
compared. 
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3.2 Results and Discussion 
3.2.1 Construction of plicA1M1T and plicA2M2TP 
To produce only Bliα, the essential genes for its biosynthesis (licA1, licM1 and licT) 
were cloned into pET-24a(+) as explained in section 3.5 to originate the plasmid 
plicA1M1T. A similar approach was carried out for Bliβ production. In this case, the 
licA2, licM2, licT and licP genes were inserted in the same plasmid to produce the 
plicA2M2TP plasmid, as explained in section 3.5.2. Both plasmids were transformed in 
E. coli BL21-Gold(DE3) cells, producing BpA1M1T (Bliα) and BpA2M2TP (Bliβ) 
strains. 
In order to understand if the lichenicidin peptides were being produced by these new 
expression systems, a colony bioassay was performed where, BLic5∆A1 (Bliβ) and 
BLic5∆A2 (Bliα) were used as complementary producer strains (Figure 20). 
 
Figure 20 - (A) Bioassay of the BpA1M1T (A1M1T) strain with the complementary producer BLic5∆A1 (∆A1). 
The strain BLic5ΔA1 (∆A2), producing Bliα was used as a negative control. (B) Bioassay of the BpA2M2TP 
(A2M2T) strain with the complementary producer BLic5∆A2. BpA2M2TP presented activity when acting 
synergistically with BLic5∆A2 but not with BLic5∆A1. (A,B) BLic5∆A1 and BLic5∆A2 were bioassayed side-by-
side, as positive control. 
As shown in Figure 20, the strain containing the plicA1M1T showed no synergy 
activity with the BLic5∆A1 strain against M. luteus. This suggested that Bliα was not 
produced. Despite several attempts using this strategy, it was not possible to obtain a 
Bliα-producer strain. One possible explanation relies on the fact that the α-peptide could 
possivly present some activity against the host cell due to its mode of action. In fact, 
studies show that the α-peptide is the first to attache to the cell membrane, binding 
preferentially to lipid II, but also to lipid I, thereby preventing peptidoglycan 
biosynthesis and working as doking site for the β peptide (Oman & van der Donk, 
2009). Thus, only cells containing possibly interrupted genes will survive, once the 
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peptide is not correctly produced avoiding the attachment to the producer cell 
membrane. Another explanation could be related with the expression of the immunity 
genes that are absent in this strain. Some studies reference that the over expression of 
the immunity genes lead to enhanced lantibiotic production (Koponen, et al., 2004, Hu, 
et al., 2010). This would imply that if the host contains improved protection against the 
peptides, it could increase their production levels. This hypothesis was not considered 
for the BpA1M1T strain construction, since it was previously described that Bliα was 
produced in the absence of the immunity genes, licFGEHI, in E. coli (Caetano, et al., 
2011).  
The strain containing the plicA2M2TP plasmid presented bioactivity when working 
synergistically with BLic5∆A2 (Bliα) (Figure 20). This result showed that a fully active 
Bliβ peptide was being produced by BpA2M2TP strain. In this strain, the immunity 
genes were also not present in this strain ant still, the Bliβ peptide was produced. Since 
it was possible to obtain this strain, a comparison of the Bliβ production levels by the 
expression systems available was performed and is presented in the following section. 
 
3.3 Comparison of Bliβ production levels 
To compare the Bliβ production levels between the available systems the E. coli 
strains were grown in liquid media and the peptides were extracted from the culture. 
These strains included E. coli BpA2M2TP, E. coli BLic5∆A1 (pLic5∆A1), E. coli 
BLic5∆A1∆A2+plicA2 (pET-24a(+) and licA2) and E. coli BLic5∆A1∆A2+pUCA2 
(pUC19a and licA2) (Table 4, section 3.5.1). After extraction, the same sample of each 
replicate was divided into two tubes. One was used to perform a bioassay and the other 
was analyzed by HPLC-ESI-MS. Both strategies were carried out to compare the 
production levels of Bliβ. 
Regarding the quantification by bioassay, serial dilutions of each replica were 
performed and tested against M. luteus. The value of the last well showing inhibition 
was considered to calculate the arbitrary units per milliliter (AU/mL).  
This value was used to compare the bioactivity of the various samples. Thus, higher 
AU/mL values will indicate the presence of higher amounts of the Bliβ peptide. 
The results (Figure 21) showed that bioactivity was similar in all the tested strains. 
Nevertheless, the extract obtained from BpA2M2TP strain seems to have a slightly 
decreased activity. This suggests that the amounts of Bliβ peptide produced by this 
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strain should be lower than those of the other strains. One possible explanation could be 
the need for other genes of the gene cluster that are absent only in this strain. 
 
Figure 21 – Quantification of Bliβ production by bioassay against M. luteus.  The AU/mL corresponds to the last 
well of the successive double dilutions that showed activity. ∆A1 – BLic5∆A1; A2M2TP – BpA2M2TP; pETA2 – 
BLic5∆A1∆A2+plicA2; pUCA2 – BLic5∆A1∆A2+pUClicA2. 
 
In order to have a more accurate outcome, these results obtained by bioassay should 
always be compared with those obtained with quantification data retrieved from HPLC-
ESI-MS/MS analysis (Figure 22).  
 
Figure 22 – Quantification of Bliβ production by HPLC-ESI-MS/MS. ∆A1 – BLic5∆A1; A2M2TP – 
BpA2M2TP; pETA2 – BLic5∆A1∆A2+plicA2; pUCA2 – BLic5∆A1∆A2+pUClicA2. 
The MS analysis evidenced the lower Bliβ production by BpA2M2TP strain and the 
higher yield by BLic5∆A1 strain. The major difference observed between bioactivity 
and MS results was with BLic5∆A1∆A2+pUClicA2 strain. This can be due to the fact 
that the bioassay method is not very precise and probably the production differences are 
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quite small to induce major variations in the inhibition areas. Thus, lower variations in 
the production levels would be difficult to detect when using a phenotypic method. The 
mass spectrometry analysis is much more precise and reliable. Moreover it was 
observed that the standard deviations obtained for the samples analyzed by MS were 
high. This indicates the discrepancy of the production levels detected between 
biological replicas. Therefore in future studies, the analysis of a higher number of 
replicates would be suggested in order to improve the accuracy of the results. 
 
3.4 Conclusion 
Considering all of the results herein presented, it seem reasonable to state that it is 
possible to produce each lichenicidin peptide independently and under the control of the 
E. coli promoter, without needing the original regulatory proteins to control the 
biosynthesis. This is supported by the fact that Bliβ was produced by BpA2M2TP 
strain. However, Bliα biosynthesis using the BpA1M1T strain it could not be achieved. 
Thus, further investigation is required in order to understand why the host was not able 
to cope with the vector containing the essential genes to Bliα production and how this 
problem could be overpassed. Moreover, MS results suggest that the new system 
developed (BplicA2M2TP) was not beneficial for Bliβ production. Therefore, additional 
studies should be performed to clarify if such system can be improved. 
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3.5 Experimental Procedures 
3.5.1 Bacterial strains and cultivation media 
The characteristics of the E. coli strains containing the lichenicidin cluster and used 
in this section are presented in Table 4. These strains were maintained in Luria-Bertani 
agar (LA; Merck) plates or grown in Luria-Bertani broth (LB; Merck) at the 
appropriated temperature. Liquid cultures were performed using medium M containing 
10 g/L of NaCl, 10 g/L of tryptone, 5 g/L of yeast extract, 10 g/L of KH2PO4, with a 
final pH of 6.5, adjusted with NaOH (Mendo, et al., 2004).  
 
Table 4 – Description of the E. coli strains used in this section. LBM stands for strain belonging to Laboratory of 
Molecular Biotechnology. 
Strain Description Phenotype Reference 
BLic5ΔA1 
E. coli BL21-Gold(DE3) containing the 
pLic5ΔA1 fosmid (pLic5 with licA1 gene 
deleted) 
Clo
R (Caetano, et 
al., 2011) 
BLic5ΔA2 
E. coli BL21-Gold(DE3) containing the 
pLic5ΔA2  fosmid (pLic5 with licA2 gene 
deleted) 
Clo
R
 
(Caetano, et 
al., 2011) 
BLic5ΔA1A2 
E. coli BL21-Gold(DE3) containing the 
pLic5ΔA1A2  fosmid (pLic5 with licA1 
and licA2 genes deleted) 
Clo
R
 LBM 
BpA1M1T 
E. coli BL21-Gold(DE3) containing the 
plicA1M1T plasmid (pET-24a(+) with 
licA1, licM1 and licT genes inserted) 
Kan
R
 Clo
R
 This study 
BpA2M2TP 
E. coli BL21-Gold(DE3) containing the 
plicA2M2TP plasmid (pET-24a(+) with 
licA2, licM2, licT and licP genes inserted) 
Kan
R
 Clo
R
 This study 
BLic5ΔA1∆A2 + plicA2 
E. coli BL21-Gold(DE3) containing the 
pLic5ΔA1A2  fosmid (pLic5 with licA1 
and licA2 genes deleted) and plicA2 (pET-
24a(+) with licA1 gene) 
Kan
R
 Clo
R
 
(Cruzeiro, 
2012) 
BLic5ΔA1∆A2 + pUCA2 
E. coli BL21-Gold(DE3) containing the 
pLic5ΔA1A2  fosmid (pLic5 with licA1 
and licA2 genes deleted) and pUCA2 
(pUC19a with licA2 gene) 
Amp
R
 Clo
R
 
(Cruzeiro, 
2012) 
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3.5.2 Construction of plicA1M1T and plicA2M2TP 
3.5.2.1 Amplification of the fragments 
The construction of the plasmids plicA1M1T and plicA2M2TP involved two-step 
cloning of PCR products. To obtain the plicA1M1T plasmid, three different strategies 
were used and are represented in Figure 23. For plicA2M2TP plasmid construction, 
licA2M2 was amplified and cloned in pET-24a(+) plasmid between the BamHI and NotI 
restriction sites. The second step involved the insertion of licTP amplification in the 
NotI restriction site of plicA2M2 plasmid. 
The amplification of licA1M1, licA2M2, licT and licTP fragments was performed in a 
50 µL reaction containing 0.5 μL of dNTPs (25 mM), 10 μL of Herculase II Buffer 
(5X), 1 μL of DMSO, 1.25 μL of each primer (10 pmol/μL), 100-400 ng of total DNA 
of B. licheniformis I89 and 5 U of Herculase II DNA polymerase. The primers applied 
are listed in Table 5. 
  
Figure 23 – General plan of experiments to construct plicA1M1T. a) and b) first, licA1M1 was 
inserted followed by licT; c) insertion of licT, followed by licA1M1; a) licT with same cohesive 
ends. 
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Table 5 - List of primers used to perform the amplifications of licA1M1, licA2M2, licT and licTP genes. In bold 
is represented the recognition site for the restriction enzyme used. The initiation codon is underlined. 
Primer Primer sequence (5’→3’) 
Restriction 
Enzyme 
Comp_licA1_Fw AGGTGGGATCCATGTCAAAAAAGGAAATG BamHI 
Comp_licM1_Rv CATAGATTCTCGAGTTAAAACACGTTTTC XhoI 
Comp_licM1_Rv_Not CTAGATTGCGGCCGCTTAAAACACGTTTTC NotI 
licT_RBS_Xho_Fw TACTCGAGAGGAGGTATAAGGCATGTTTTTTCATAAGA XhoI 
licT_RBS_Not_Fw TAGCGGCCGCAGGAGGTATAAGGCATGTTTTTTCATAAGA NotI 
Comp_licT_Rv GGTGGTGGTGCTCGAGTCACATCATCACCTCTGCAGATT XhoI 
Comp_licA2_Fw ATCAGGATCCATGAAAACAATGAAAAATTCAG BamHI 
Comp_licM2_Rv TAGTGCGGCCGCTCACCTGCCCGTCGGAATATC NotI 
Comp_licP_Rv TTTTGCGGCCGCTCACTCCTTGTTCATCATTTTC NotI 
 
The amplification program included 95 ºC for 2 min, followed by denaturation at 
95 ºC for 20 sec, annealing at specific temperature (Table 6) for 20 sec and extension at 
72 ºC for specific time (Table 6). The final extension step was performed at 72 ºC for 3 
min. 
 
Table 6 - Annealing temperature and extension time used in the PCR reactions performed to amplify licA1M1, 
licA2M2, licT and licTP genes. 
 
Amplification Primers Tannealling (ºC) 
Extension time 
(min) 
licA1M1 
Comp_licA1_Fw 
Comp_licM1_Rv 
54 4 
licA1M1 
Comp_licA1_Fw 
Comp_licM1_Rv_Not 
54 4 
licT 
licT_RBS_Xho_Fw 
Comp_licT_Rv 
57 3 
licT 
licT_RBS_Not_Fw 
Comp_licT_Rv 
57 3 
licA2M2 
Comp_licA2_Fw 
Comp_licM2_Rv 
58 4 
licTP 
licT_RBS_Not_Fw 
Comp_licP_Rv 
56 4  
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3.5.2.2 Digestion 
In order to insert the fragments amplified into the chosen vector, and considering the 
experiments previous listed, a range of digestions were performed to cover all the 
situations (Table 7). All reactions were carried out in a final volume of 40 µL 
containing 1000 ng of insert or 700 ng of plasmid, the appropriate enzyme and reaction 
buffer (Fermentas; Table 8). The digestions were performed at 37 
o
C for 1 hour and 
purified with NZYGelpure kit (NZYtech) according to the manufacturer’s instructions 
(Appendix 10). 
 
Table 7 – Table of digestion reactions performed to all plasmid used and respective fragments. 
 licA1M1 licT licA2M2 licTP 
pET-24a(+) 
BamHI/XhoI 
BamHI/NotI 
NotI/XhoI BamHI/NotI - 
plicA1M1 - 
XhoI 
NotI/XhoI 
- - 
plicT BamHI/NotI - - - 
plicA2M2 - - - NotI 
 
 
Table 8 – List of buffers and restriction enzymes used in the digestion reactions performed. The double 
digestions were prepared according with DoubleDigestTM (Fermentas) indications. 
 
BamHI/NotI BamHI/XhoI NotI/XhoI XhoI 
Buffer O (1x) Buffer BamHI (1x) Buffer O (1x) Buffer O (1x) 
10 U of NotI 
40 U of BamHI 
10 U of BamHI 
20 U of XhoI 
10 U of NotI 
20 U of XhoI 
10 U of XhoI 
 
Ligation reactions were performed in a total volume of 20 µL containing 50 ng of 
plasmid DNA, 150 ng of DNA insert, 1X T4 DNA ligase buffer and 1 µL of T4 DNA 
ligase (Fermentas). All reactions were incubated at 22 
o
C for 1 hour on a thermocycler 
and conserved at -20 
o
C until further use. 
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3.5.2.3 Transformation 
The subcloning procedures were carried out with chemically competent E. coli DH5α 
cells, using 5 µL of the ligation for transformation procedure. Once the final plicA1M1T 
and plicA2M2TP plasmids were obtained, 2 µL of the plasmid were used to transform 
chemically competent E. coli BL21-Gold(DE3) cells. Transformations were performed 
by heat shock using chemically competent E. coli cells as described in the Appendix 4. 
Transformants were selected overnight at 37 
o
C on LA plates containing 50 µg/mL of 
Kan. 
Positive clones were selected using colony-PCR with the appropriate primers using 
the protocol described in Appendix 8. 
 
3.5.2.4 Screening and Bioassay 
The colony-bioassay was performed as described in 2.4.7. 
3.5.3 Comparison of Bliβ production levels 
3.5.3.1 Preparation of extracts 
Bacterial strains were cultured and peptide’s extraction was performed as described 
in 2.4.7.1. 
3.5.3.2 Quantification by bioassay 
The strains producing exclusively Bliβ peptide do not exhibit antibacterial activity 
against M. luteus. Therefore, in order to measure the bioactivity of these extracts, the 
Bliα peptide needed to be provided on the agar plates. These agar plates were prepared 
with the supernatant of an E. coli BLic5∆A2 culture. For this, E. coli BLic5∆A2 was 
pre-cultured (Medium M supplemented with 12.5 μg/mL of Clo), at 37 oC, 180 rpm, 
overnight) and 1 mL was used to inoculate 100 mL of medium M. After 24 h at 37 
o
C, 
180 rpm, the culture was centrifuged twice at 12 000 xg for 5 min and the supernatant 
filtered using a 0.45 µm nitrocellulose filter. 6.25 mL of this supernatant was added to 
42.75 mL of medium M containing 1.75 % agar for each plate. After mixing, M. luteus 
was added to a final OD600nm of 0.02 and the plates prepared.  
The extracts bioactivity was quantified as previously described in section 2.4.7.2. 
  
 
 
 
 
 
 
CHAPTER IV 
 
RANDOM MUTAGENESIS OF BLI PEPTIDE 
 
Random Mutagenesis of Bliα Peptide 
53 
 
4.1 Background 
Lantibiotics present a major advantage over the usual antibiotics in what concerns to 
bioengineering, since the final peptide is gene encoded and thus, much more amenable 
to engineering strategies. Those approaches can contribute not only to produce peptides 
with altered biological, chemical and physical properties but also to the lantibiotics 
structure-function elucidation (Field, et al., 2010). Indeed, several approaches have been 
developed during the last years in order to obtain peptides with different characteristics 
from those of the originally produced. These changed peptides have been produced and 
studied with two major goals: i) to get deeper insights in structure-activity relationships 
and ii) to obtain improved variants in terms of activity and/or production (Appleyard, et 
al., 2009, Field, et al., 2010). 
The most common approaches used nowadays are related with mutagenesis 
techniques, usually random mutagenesis or site-directed mutagenesis (Field, et al., 
2010). This last one, can also include the site-saturation mutagenesis, in which it is tried 
to generate all possible mutations at a specific site (Appleyard, et al., 2009). The site-
directed mutagenesis implies a mutation in a specific nucleotide while in random 
mutagenesis several mutations can be inserted randomly within the gene of interest. All 
of these methods have already been applied to the lantibiotic’ study (Field, et al., 2007, 
Appleyard, et al., 2009, Field, et al., 2010). 
In the present study random mutagenesis was the method chosen. The main 
advantage of this system is that is possible to obtain a large number of mutants 
containing the most variable mutations, which might increase the different activities 
observed. Also, this technique does not require previous knowledge about the gene 
sequence, once the mutations are inserted randomly. On the contrary, it requires an easy 
screening method, since sometimes it is not easy to understand which mutation is 
causing a specific phenotype. 
For this approach, licA1 from the original B. licheniformis I89 was used to perform 
mutagenesis. Mutations are randomly inserted in the selected using a procedure that 
uses a high frequency of error insertion DNA polymerase; mutants are generated that 
can differ in a single or many nucleotides or may even include insertions. Then, the 
mutated PCR products were ligated to the pUC19a vector and introduced into an E. coli 
strain containing the pLic5 fosmid in which licA1 and licA2 were deleted 
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(BLic5∆A1∆A2 strain). With this, it was expected to obtain a number of mutations that 
produce could interfere with the bioactivity and/or production of Bliα. 
. 
4.2 Results and Discussion 
4.2.1 licA1 library 
To produce a library of licA1 mutants, the original licA1 gene was submitted to two 
cycles of amplification with Mutazyme II, in order to increase the number of induced 
mutations. The resulting PCR product that undergone random mutagenesis, was ligated 
with pUC19a plasmid and transformed in E. coli BLic5∆A1∆A2, which includes the 
whole lichenicidin gene cluster except both structural genes. From this procedure, 
approximately 3030 clones were picked and tested by colony-bioassay using 
BLic5∆A1∆A2+pUClicA1 as positive control. 
 
4.2.2 Analysis the library by colony-bioassay 
The first screening of the library was performed by colony-bioassay, in order to 
narrow the number of clones that would be further investigated. The bioassay was 
performed by replica plating using M. luteus as indicator strain. To obtain inhibition 
areas, the supernatant of the BLic5∆A1 was incorporated in the bioassay medium to 
provide the complementary Bliβ peptide. The positive control 
BLic5∆A1∆A2+pUClicA1 was always included in all the tested plates.  
The analysis of the plates revealed the presence of several inhibition halos (Figure 
24). The comparison of such areas with that of the positive control was used to 
recognize clones with no activity (or very reduced activity) and clones with apparently 
increased activity. Still, among the negative clones it was necessary to confirm the 
presence of licA1 gene into the vector. This was performed using colony-PCR as 
described in Appendix 8. After this, 1625 clones incapable of inhibiting the indicator 
strain (but containing the licA1 gene) and 90 clones with possible improved properties 
were identified. Thus, these strains were selected for further analysis. 
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4.2.3 Analysis of Bliα mutations  
In the present work, the licA1 nucleotide sequence of only 10 clones was analyzed. 
Among those, 5 clones possessing no activity (A1.1, A1.10, A1.12, A1.16 and A1.23) 
and 5 clones with increased activity (A1.13, A5.3, A5.14, A6.30 and A12.15). Before 
sequencing, a new bioassay was performed to confirm the initial phenotype identified 
(Figure 25). 
 
Figure 25 – Bioassay with the clones to be sequenced. (A) negative clones; (B) positive clones with increased 
activity. 
 
After sequencing, the results were analyzed by comparing both the nucleotide and 
amino acids sequences with the original licA1 sequence. With this approach, the 
Figure 24 – Example of same bioassay plates; several inhibition halos are visible; 
comparison of the halo size with these of the positive control allowed to check for increased 
activity. 
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nucleotide mutations that do not influence the amino acid sequence (silent-mutations) 
could also be identified. 
Concerning clones with no activity it is important to mention that the absence of 
bioactivity can be due to an incorrect production of the peptide. This was observed for 
clones A1.10 and A1.23. In the first case, a frame shifting mutation was identified. In 
the second, a stop codon was inserted. Thus, these clones will not be considered for 
further tests. Regarding the remaining three tested clones, the detected mutations 
resulted in amino acid substitution as shown in Figure 26. 
 
As shown in Figure 26 each sequence presented at least one mutation in the sequence 
of the structural gene. However, some of them showed more than one mutation, 
including mutations in the leader sequence. In such cases, it is difficult to understand if 
the absence of bioactivity is due to the accumulation of mutations or to a single specific 
mutation. Thus, if such clones were further studied, other techniques such as site-
directed mutagenesis should also be used in order to confirm which mutation(s) is the 
responsible for the loss of activity. 
For clones A1.1 and A1.12, mutations were identified in both the leader sequence 
and the propeptide. Considering A1.1, the clone possesses a Thr24Ala mutation. In fact, 
this mutation was already performed in a previous study (Caetano, et al., 2011), which 
resulted in the complete loss of activity. Such mutation should prevent the formation of 
a MeLan ring, thus, could contribute to its structural instability, and the phenotype 
observed should result from the absence of its production as described by Caetano et al. 
(2011).  
Figure 26 – Comparison between the selected clones and the original licA1 leader sequence and propeptide. 
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Regarding the clone A1.12, it is difficult to understand which mutation can cause the 
observed phenotype. However, it was found that both A1.12 and A1.16 have a 
Leu→Ser substitution in the propeptide region nearby the ring forming amino acids. 
Such mutations have been associated with both decreasing and increasing of mersacidin 
(analogous to Bliα peptide) bioactivity (Appleyard, et al., 2009). In the same study, 
Leu→Gln substitutions (as observed in clone A1.12) induced the production of low 
levels of mersacidin. The substitution of Val→Glu was not previously reported. 
Further research must be developed to help clarifying the effect of mutations in the 
leader sequence. However, previous studies with nisin and Pep5 lantibiotics, suggest 
that mutations into this region may influence the maturation and secretion processes of 
the final peptide, leading to an abolishment of the activity (Vandermeer, et al., 1994, 
Neis, et al., 1997). 
Regarding, the Bliα producers that seemed to present increased bioactivity, 3 clones 
did not have any mutation and 1 possessed a silent mutation. Thus, in such cases, the 
amino acid sequence of the final peptide should not be altered. Such result highlights 
the unreliability of phenotypic assays to detect improved variants. Only one clone 
(A1.13) presented a mutation Ser-5Cys. This could be interesting to investigate further 
once generally the lantibiotic leader sequences do not possess any Cys amino acid. 
However, analytical data should be obtained for this mutant before assuming that this 
mutation improves the activity and/or production of Bliα. 
 
4.3 Conclusion 
In this chapter a random library of the licA1 gene was successfully produced and its 
bioactivity screened. Insertion of the mutations results mainly in non-producing clones. 
Random mutagenesis is a useful tool to produce mutants with different levels of 
bioactivity due to its high frequency of mutation insertion. However, a major drawback 
of this technique is due to the potential insertion of several mutations simultaneously. 
This would prevent the complete understanding of which mutation(s) is directly related 
with a phenotype change, without the application of other complementary analyses such 
as site-directed mutagenesis. In order to withdraw significant conclusions of the library 
herein constructed, more clones should be sequenced and the study must be 
complemented with other analytical methods to ensure more precise outcomes.  
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4.4 Experimental Procedures 
4.4.1 Random Mutagenesis library construction 
To perform random mutagenesis it was used GeneMorph II Random Mutagenesis kit 
(Agilent). Mutazyme II exhibits high misinsertion and misextention frequencies in such 
a way that mutation rates of 1 to 16 mutations per kb can be achieved using only one set 
of optimized PCR conditions. 
licA1 gene was amplified from pUClicA1 vector (pUC19a plasmid containing licA1 
gene). A dilution of the pDNA was performed in order to obtain an initial amount of the 
target gene of 0.1 ng using approximately 1 µL of the template for each reaction. The 
primers used (Table 9) were mixed together, in order to obtain a final concentration of 
250 ng/µL of each primer. 
 
Table 9 – Primers used to amplify licA1 for random mutagenesis procedure and colony-PCR screening. 
Represented in bold de recognition site for the restriction enzyme and underlined the start codon. 
 
The first reaction was performed in a final volume of 50 μL containing 0.5 μL of 
primermix (250 ng/μL), 1 ng of pDNA, 5 μL of Mutazyme II buffer (10X), 1 μL of 
dNTP mix (25 mM) and 5 U of Mutazyme II enzyme. The fragment was amplified at 95 
ºC for 2 min, followed by 30 cycles of denaturation at 95 ºC for 30 sec, annealing at 50 
ºC for 30 sec and extension at 72 ºC for 1 min. The final extension included 10 min at 
72 ºC. 
After the PCR reaction, 5 µL of the product were analyzed by agarose gel 
electrophoresis. Afterwards, the mixture of PCR products were purified using NZYtech 
kit (see Appendix 10) and its concentration was determined using Qubit (Appendix 11). 
This product was used for a second PCR reaction performed in the same conditions as 
the first PCR and using 1 ng of DNA. 
After purification and DNA quantification, 1000 ng of DNA were digested in a 
reaction of 60 µL containing 1X of BamHI buffer, 30 U of BamHI and 60 U of NcoI 
restriction enzyme. The mixture was then incubated at 37 
o
C for 2 hours. Afterwards, 40 
µL of distilled water were added to the reaction and it was purified using the NZYtech 
Primer designation Primer sequence (5’→3’) 
Restriction 
enzyme 
licA1_fw_NcoI TATCCATGGCTATGTCAAAAAAGGAAATG NcoI 
licA1_rv_BamHI TATGGATCCTTAGTTACAGCTTGG CATG BamHI 
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kit. 3 µL of this product were then analyzed by agarose gel electrophoresis. The 
obtained fragments (150 ng) were ligated to the previously digested pUC19a vector (50 
ng) in a reaction containing 1X T4 DNA ligase buffer and 2 µL of T4 DNA ligase 
enzyme in a final volume of 40 µL. the reaction was allowed to occur at 22 
o
C for 1 
hour using a thermocycler.  
10 µL of the ligation were used to transform 100 µL of chemically competent E. coli 
BLic5∆A1∆A2:Apra cells by heat shock (see Appendix 4). After 1 hour at 37 oC, the 
culture was centrifuged for 2 min at 6000 xg. The supernatant was then discarded and 
the pellet was resuspended in 500 µL of LB medium. 100 µl of culture were plated in 
each LB agar plate containing 12.5 µg/mL of Clo, 50 µg/mL of Apra and 100 µg/mL of 
Amp. The plates were incubated at 37 
o
C overnight. 
 
4.4.2 Library screening by colony-bioassay 
Approximately 3000 clones were randomly picked and plated into new LB agar 
plates supplemented with the appropriate selective markers. In all the plates, the 
BLic5∆A1∆A2+pUClicA1 strain was also included. Moreover, all plates were identified 
using a system of number and letters which will allow an easier way of identify each 
clone: a letter referent to the number of the transformation, a number identifying the 
number of the plate, followed by a second number indicating the number of the clone. 
The plates were incubated overnight at 37 ºC. 
The bioactivity of each one of the selected clones was performed by colony-bioassay. 
The plates were prepared as described in section 3.5.3. However, supernatant of the 
BLic5ΔA1 strain was used instead of that of BLic5ΔA2, in order to provide the 
complementary Bliβ peptide. The clones were inoculated in the bioassay plates using 
the replica platting technique. In this case, the isolated colonies were inoculated into the 
bioassay plates, instead of using extracts. This technique is useful when it is necessary 
to test several different isolate clones, because it allows transferring several clones at 
one time. Briefly, a wood block with the same form of the plates was used in 
conjugation with a sterilized velvet piece. Such apparatus was in contact with the 
original plate for a few seconds and pressuring for a while and then transferred to the 
bioassay plate in the same conditions. It is important to take in account the orientation 
of the plates to make sure that it is possible to identify each clone and relate it with its 
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own activity in the bioassay. All plates where incubated at 37 
o
C overnight and the 
resulting inhibition areas analyzed and recorded. 
Those clones without bioactivity were submitted to colony-PCR reactions using 
DNA Taq polymerase from Promega (Appendix 8) and M13 universal primers. This 
allowed to discard eventual clones without the licA1 gene inserted into the plasmid.  
 
4.4.3 Sequencing of licA1 mutants 
From all the confirmed non-active clones, 40 were initially chosen together with 10 
clones with potentially increased bioactivity. Five clones of each group were submitted 
to nucleotide sequence determination (StabVida, Portugal). The nucleotide sequences 
were compared with that of the original licA1 gene, which sequence is available in the 
GenBank database (accession number AAU25566.1) and using CLC Sequence Viewer 
6. 
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5.1 Involvement of LicR protein in Bliα biosynthesis 
LicR protein was initially thought to be implicated in the regulation of lichenicidin 
biosynthesis, once the deletion of licR in E. coli lead to a loss of bioactivity, which was 
found to be related with the absence of functional Bliα peptide (Caetano, et al., 2011). 
However, during the preliminary tests to check for this hypothesis, an insertion in the 
licM1 gene was detected in the licR knockout strain, which causes an inactive LicM1 
protein that consequently is not able to modify LicA1 to its final conformation. A new 
knockout mutant was generated and it was possible to observe that Bliα presented 
antimicrobial activity. The expression levels of licA1 and licM1 in the presence and 
absence of licR were evaluated and did not reveal any difference. 
Considering that the regulation mechanisms in Gram negative and Gram positive 
strains are different, it was tried to perform the same study using the original producer 
strain, B. licheniformis I89. However, despite the several protocols attempted it was not 
possible to obtain a licR knockout B. licheniformis mutant yet. 
 
5.2 Production of each lichenicidin peptide independently under the control of 
E. coli determinants 
The heterologous expression system using E. coli has been used already to produce 
each peptide independently. For that and starting from the fosmid containing the whole 
gene cluster, a knockout was constructed to one of the structural genes to produce each 
peptide; in another system, both structural genes were deleted followed by 
complementation with each one of them separately inserted into a plasmid. In the 
present study, an attempt was made to insert the genes that are directly involved in the 
biosynthesis of each peptide (including structural gene, those encoding modification and 
transport proteins and also a protease in the case of Bliβ) into a cloning vector with E. 
coli determinants. 
Concerning the results obtained until now with Bliβ, it seems reasonable to suggest 
that it is possible to produce each peptide independently using E. coli transcriptional 
and translational determinants. Comparing the expression levels of Bliβ of all the 
available systems for its production, it appears that the system constructed in this study 
(BpA2M2TP) shows no advantages, once it was not possible to observe increased 
activity. 
Synopsis and Future Perspectives 
 
64 
 
The production of Bliα using the same methodology was not accomplished yet and 
this needs further investigation in order to understand why, once the host does not to 
cope well with the inserted vector. 
 
5.3 Generation of Bliα peptides showing bioactivity differences using Random 
Mutagenesis 
Considering not only the academic but also the industrial interest in the production of 
lichenicidin, the development of studies regarding the enhancement of the expression 
and/or bioactivity of the lantibiotic is important. 
The insertion of mutations within the genes can lead to phenotypic differences 
including increased or decreased activity or even no activity at all. Several techniques 
could be used to insert such mutations. In the present work, random mutagenesis was 
chosen, which allows randomly insertion of one or more mutations within a gene by a 
PCR using an error-prone polymerase. This technique was found to be useful to produce 
those mutants showing different levels of bioactivity due to its high frequency of 
mutation insertion. It is important to notice that some mutations can lead to no changes 
on bioactivity, once they may change a nucleotide without changing the final amino 
acid or even changing the amino acid that might not affect greatly the bioactivity of the 
final peptide. 
Random mutagenesis was performed for licA1 gene, in an attempt to generate Bliα 
peptides with changed activity. It was clear that the majority of the clones lost the 
ability to produce the peptide or the produced peptide is not active. This technique 
needs to be complemented with efficacious screening methods, both phenotypic and, 
mainly, quantitative. 
 
5.4 Major conclusions of the study 
The major findings and conclusions of this thesis are bellow highlighted: 
‒ LicR is not essential for the biosynthesis of Bliα peptide in E. coli (Chapter II); 
‒ The strain without licR gene presents a higher yield of lichenicidin production, 
indicating that LicR role in biosynthesis regulation in E. coli can be different from 
that usually described in lantibiotic regulation mechanisms (Chapter II); 
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‒ The production of Bliβ peptide in E. coli was possible by expressing the genes 
exclusively involved in its biosynthesis (licA2M2TP) under the control of an E. coli 
promoter. However, bioassay and analytic quantification suggested that its levels of 
production were lower when compared with systems involving the complete lic gene 
cluster (Chapter III); 
‒  Bliα production could not be achieved by cloning the genes exclusively 
necessary for the biosynthesis (licA1M1T) under the control of the T7 promoter 
(Chapter III); 
‒ A random mutagenesis library containing licA1 variants was constructed; a first 
bioactivity screening was performed revealing that the majority of the identified 
clones lost their bioactivity (Chapter IV). 
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5.5 Future perspectives 
Considering all the results obtained in the present work, it is clear that some aspects 
would benefit from further investigation, in order to clarify several aspects of 
lichenicidin biosynthesis in E. coli as well as in its natural producer B. licheniformis 
I89. 
Firstly, the development of a licR knockout B. licheniformis I89 mutant will be of 
most importance to understand if LicR protein can be involved in the regulation of the 
expression of licA1/licM1 genes. Thus, the protocols must be optimized and novel 
experiments performed in order to produce such strain. Moreover, the optimization of 
an efficacious protocol for B. licheniformis transformation could open several 
hypotheses for the study of those Gram positive strains that are hardly transformable.  
Other challenge to overcome would be the elucidation of the reasons behind the 
unsuccessful production of Bliα peptide in E. coli when the licA1M1T genes were 
expressed under the control of the T7 promoter (Bliβ peptide was achieved using the 
same host and the same vector). Also, the development of an improved expression 
system of lichenicidin in E. coli will be of major interest. This would be especially 
relevant for studies that involve the incorporation of noncanonical amino acids. 
Regarding the mutagenesis of Bliα, the identification of mutant peptides with 
increased bioactivity and/or production constitutes a major advantage. Also from the 
scientific point of view, those mutations causing changes in the peptides bioactivity are 
an interesting case of study, both for increased and decreased activity or even null 
activity. Nevertheless, only preliminary screening of the library was performed in this 
study. The identification of the mutations behind the phenotypes identified should be 
performed. Moreover, the structure and production levels of those peptides with 
interesting properties should be further investigated with analytical techniques such as 
mass spectrometry. However, these analyses should involve an increased number of 
replicas for each strain to be examined.  
This study opened perspective for future studies, namely regarding the biosynthesis 
and bioengineering of lantibiotics. 
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7.1 Appendix 1 
Preparation of selective agents 
The selective agents used in the study were prepared as stock solutions in the 
appropriate solvent and sterilized by filtration with a 0.2 µm cellulose filter, when 
required. All the stock solutions prepared are summarized in Table S1 
Table S1: Summary of the stock solutions preparation for the selective agents used in the present study. NR 
stands for non required. * Protect from light with foil paper. 
Selective agent Supplier 
Stock 
solution 
(mg/ml) 
Final 
concentration 
(µg/ml) 
Solvent Sterilization 
Ampicilin Sigma 100 100 Water Filtration 
Apramycin AppliChem 50 50 Water Filtration 
Chloramphenicol BDH 25 12.5 Ethanol NR 
Kanamycin Gibco 100 50 Water Filtration 
Tetracyclin* Sigma 20 10 Ethanol NR 
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7.2 Appendix 2 
General Strains 
The general bacterial strains used in this study are listed in Table S2. 
Table S2: List of the general strains used in this study with the reference to their genotype and supplier, when 
available. ATCC (American Type Culture Collection); FCUL (strains kindly provided by the Faculty Sciences of the 
University of Lisbon); INETI (Strain kindly provided by Dr. José C. Duarte; JIC (Jonh Innes Center); MUL 
(University of Lisbon Microorganims Collection); WWM (strains kindly supplied by Prof. Friedhelm Meinhardt from 
Westfälische Wilhelms-Universität Münster)  
Strain Source Genotype/Characteristics 
E. coli BL21 Gold Novagen E. coli B F
-
ompThsdS (rB
-
 mB
-
) dcm
+
 Tet
r
galendA Hte 
E. coli BW25113 JIC 
lacI
+
rrnBT14∆lacZ WJ16 hsdR514∆araBAD AH33 ∆rhaBAD 
LD78 
E. coli DH5α MUL 
F
-
endA1glnV44 thi-1 
recA1relA1gyrA96deoRnupGΦ80dlacZΔM15 Δ(lacZYAargF) 
U169, hsdR17(rK
-
 mK
+
), λ– 
E. coli S17-1  recA pro hsdR RP4-2-Tc::Mu-Km::Tn7 
E. coli ET12567  
F-dam-13::Tn9 dcm-6 hsdM hsdR zjj-
202::Tn10 recF143 galK2 galT22 ara-14 lacY1xyl-5 leuB6 thi-
1 tonA31 rpsL136 hisG4 tsx-78 mtl-1 glnV44 
B. licheniformisI89 INETI Lichenicidin producer (Mendo, et al., 2004) 
B. licheniformisMW3 WWM 
B. licheniformis DSM13 (∆hsdR1, ∆hsdR2); Lichenicidin 
producer 
Micrococcus luteus ATCC 9341 MUL Indicator strain 
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7.3 Appendix 3 
General Vectors 
Table S3: List of the general plasmids and fosmid used in this study, where MW refers to the molecular weigh of 
the vectors. Ampicillin (Amp); Apramycin (Apra); Chloramphenicol (Clo); Kanamycin (Kan). JIC (Jonh Innes 
Center); UC-USA (plasmids kindly provided by Prof. Daniel Portnoy from University of California, USA). 
Vector Source 
MW 
(Kb) 
Selective 
marker 
Observations 
pKSV7 UC-USA 6.9 Amp
R
, Clo
R
 
E. coli/Bacillus shuttle vector. ColE1 and 
oripE194TS. oripE194 replicates at 32oC and segregates 
at 42oC. 
pET-24a(+) Novagen 5.3 Kan
R
 
Possess an N-terminal T7●Tag® sequence plus an 
optional C-terminal. His●Tag® sequence. 
pKD20 JIC 6.1 Amp
R
 
Low copy plasmid encoding the ʎ Red 
recombinase (ɣ, β, exo), which promote a greatly 
enhanced rate of recombination when using linear 
DNA. Possesses an optimized RBS for efficient 
translation of ɣ and expresses ɣ, β, and exo from the 
arabinose-inducible ParaB promoter. It is also a 
temperature-sensitive replicon to allow for its easy 
elimination. 
pIJ733 JIC 4.3 Apra
R
 
The ApraR disruption cassette was cloned into the 
EcoRV site of pBluescript SK II (+). The cassette is 
flanked by FRT sites (FLP recognition targets) which 
allows FLP-mediated excision of the cassette. 
pUC19a Fermentas 2.7 Amp
R
 
High copy number E. coli plasmid; pMB1 
replicon; region of E. coli lac operon containing a CAP 
protein binding site, promoter Plac, lac repressor 
binding site and the 5’-terminal part of the lacZ gene 
encoding the N-terminal fragment of beta-galactosidase 
which can be induced by IPTG, includes NcoI and NheI 
resticiton sites. 
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7.4 Appendix 4 
Preparation and transformation of chemically competent E. coli cells 
7.4.1 Preparation of competent cells by calcium-chloride method 
Chemically competent cells were prepared using an adaptation of the procedure described by 
Sambrook and Russell (Russell & Sambrook, 2001). The strain was inoculated in 10 mL of LB 
medium supplemented with the appropriated selective marker, overnight at 37 
o
C, 180 rpm. 50 
mL of fresh LB medium supplemented with the appropriate antibiotic were inoculated with the 
described pre-culture and the culture was grown at 37 
o
C, 180 rpm, to an OD600nm of 
approximately 0,3. The culture was then centrifuged at 4 
o
C for 2 min at 6300 xg and the 
resulting pellet was washed with 13 mL of ice-cold 0.1 M of MgCl2 and centrifuged again as 
mentioned. 25 mL of 0.1 M CaCl2 solution were used to wash the pellet and the cells were then 
incubated on ice during 20 min and centrifuged once more as described. Finally the cells were 
resuspended in 1 mL of cryopreservation buffer (CaCl2 0.1M, 15 % (v/v) glycerol) which was 
divided in 50 µL aliquots and stored at -80 
o
C until use. 
 
7.4.2 Transformation 
An aliquot of 50 µL of the abovementioned stored cells were thawed on ice and the desired 
DNA was added (~5-100 ng of plasmid DNA or 5 µL of ligation reaction). The mixture was 
incubated on ice for 15 min and transferred to 42 
o
C for 45 sec. The tube was immediately 
placed on ice for 2 min and 1 mL of LB medium was added. The cells were grown for 1 hour at 
37 
o
C, 180 rpm, and the culture was centrifuged at 2300 xg for 1 min to collect cells. The most 
part of supernatant was discharged and the pellet was resuspended in the remaining supernatant. 
Finally cells were spread on LB agar plates containing the appropriate antibiotic which were 
incubated at 37 
o
C, overnight. 
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7.5 Appendix 5 
Preparation and transformation of electrocompetent E. coli cells 
7.5.1 Preparation of electrocompetent cells 
 
The desired strain was grown in 10 mL LB medium supplemented with the appropriate 
selective marker, at 30 
o
C, 160 rpm, and overnight. 100 µL of this pre-culture were used to 
inoculate 10 mL of fresh LB medium containing 20 mM of MgSO4 and the antibiotic. The 
culture was grown in the same conditions until it reaches an OD600nm of approximately 0.4. The 
culture was then centrifuged at 3300 xg for 5 min and 4 
o
C. The supernatant was discarded and 
the pelleted cells were resuspended in 10 mL of ice-cold 10 % glycerol by gently mixing. The 
suspension was centrifuged as above and the same procedure was repeated. After the final 
centrifugation, the cells were resuspended in 100 µL of 10 % glycerol and kept at 4 
o
C until use, 
since this procedure was always performed in the same day of transformation. The selective 
markers used in E. coli BW25113/pKD20/pLic5 growth were 100 µg/mL of Apra and 12.5 
µg/mL of Clo. 
 
7.5.2 Electroporation 
The freshly prepared electrocompetent cells were electroporated using a Bio-Rad 
MicroPulser Electroporator: 50 µL of cells were mixed with 100 to 200 ng of DNA and 
maintained on ice. The mixture was transferred to a 0.1 or 0.2 cm ice-cold electroporation 
cuvette and a single pulse was applied using 2.5 kV (the expected time constant was 4.5-4.9 
ms). Immediately it was added 1 mL of ice-cold LB medium to the cells and the suspension was 
incubated at 30 or 37 
o
C (depending if replication or segregation of pKD20 was desired, 
respectively) for 1 hour at 180 rpm. The culture was then centrifuged at 2300 xg for 1 min, 
resuspended in the remaining supernatant and spread in LB agar plates containing the 
appropriate antibiotics. The plates were incubated at 30 or 37 
o
C overnight. The selection of E. 
coli BW25113/pKD20/pLic5 strains possessing the desired gene interruption was performed 
with 100 µg/mL of Apra and 12.5 µg/mL of Clo at 37 ºC. 
 
  
Appendices 
 
82 
 
7.6 Appendix 6 
Extraction of plasmid DNA 
7.6.1 Mini-preparations 
The routine extraction of plasmid DNA from E. coli was performed with QIAprep Spin 
MiniPrep Kit (QIAGEN) according to manufacturer’s instructions. Briefly, the bacterial culture 
containing the desired plasmid was grown in LB medium with the appropriate selective marker, 
at 37 
o
C, 180 rpm, overnight. 5 mL of the culture were centrifuged at 6000 xg for 2 min and the 
supernatant was discharged. The remaining pellet was completely resuspended in 250 µL of 
Buffer P1 (with RNase A added). 250 µL of Buffer P2 were then added and the suspension was 
mixed thoroughly by inverting the tube 4-6 times (without vortexing). At that point, if LyseBlue 
was been added to Buffer P1, the suspension will turn blue. Neutralization was performed by 
the addition of 350 µL of Buffer N3 and by immediately mixing thoroughly by inverting the 
tube 4-6 times (until the solution becomes cloudy). The lysate was centrifuged for 5 min at top 
speed in a table-top microcentrifuge and the supernatant was transferred to a QIAprep spin 
column. After a centrifugation for 1 min at top-speed the flow-through was discharged, the 
column was placed back into the same collection tube and washed by the adding of 0.5 mL of 
Buffer PB and centrifuging for 1 min. The flow-though was discharged and the column was 
washed again with 0.75 mL Buffer PE (with ethanol added) followed by centrifugation as 
described. The flow-through was discarded and the column, placed into the same collection 
tube, was centrifuge for an additional 1 min to remove residual ethanol. Finally the column was 
transferred to a sterile 1.5 mL microcentrifuge tube and the elution og plasmid DNA was 
performed by the addition of 40 µL of sterile distilled water to the center of the column, 
incubation at room temperature for 1 min and centrifugation at top-speed for 1 min. 
 
7.6.2 Maxi-preparations 
When a higher concentration of plasmid DNA was required, the extraction was performed 
from an initial culture of 100 mL grown overnight at 37 
o
C, 180 rpm in LB medium 
supplemented with the appropriate selective marker.  
The bacterial culture was centrifuged at 5000 xg for 6 min and the pelleted cells were 
resuspended in 6 mL of Solution I containing lyzozyme and incubated at room temperature for 5 
min. 16 mL of freshly prepared solution II was added to the suspension in order to lysate cells. 
Then 12 mL of the alkaline Solution III were added and the solution was gently mixed for 3 
min. The mixture was incubated on ice for 10 min and then centrifuged at top speed for 15 min 
at 4 
o
C to in order to separate the plasmid DNA from the cells debris and chromosomal DNA. 
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The supernatant containing the plasmid DNA was recovered avoiding the white precipitate of 
residual cell debris. 0.6 volume of isopropanol was added to the supernatant and incubated at 
room temperature for 15 min to precipitate the plasmid DNA. The DNA was recovered by 
centrifugation at 9600 xg for 15 min and the pellet was washed once with 5 mL of 70 % 
ethanol. The ethanol was removed by centrifugation, as described above, and completely 
evaporated. The pellet was resuspended in 1 mL of TE. 
The sample was then treated in order to remove RNA by the addition of DNase-free RNase 
A (Roche) to a final concentration of 2 mg/mL and incubated at 37 
o
C for 1 hour. The extraction 
was performed with Phenol/CIA (Invitrogen): 1 volume of Phenol/CIA was added to remove 
proteins and the mixture was centrifuged at top speed for 5 min. The upper organic phase was 
transferred to a new tube and 1/10 volume of sodium acetate and 0.6 volume of isopropanol was 
added to precipitate nucleic acids. The mixture was incubated at room temperature for 30 min 
and centrifuged at top speed for 15 min at 4 
o
C. The pellet was washed with 500 µL of 70 % of 
ethanol and a last centrifugation at top speed for 15 min was performed. The ethanol was 
removed and the tube was air-dried to evaporate the residual ethanol. Plasmid DNA was 
resuspended in 100 µL of sterile distilled water. 
Solutions: 
Solution I: 50 mM Tris-HCl and 10 mM EDTA. 
Solution II: 200 mM NaOH, 1% (w/v) SDS. 
Solution III: 3 M potassium acetate, pH 6 .5. 
TE: 10 mM Tris-HCl and 1 mM EDTA, pH 8.0. 
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7.7 Appendix 7 
Extraction of fosmid from E. coli 
To extract fosmid DNA, columns cannot be used because of DNA large size. However, the 
protocol can be performed using the reagents from the QIAprep Spin MiniPrep Kit (QIAGEN). 
Next, two protocols are described to extract fosmid DNA: one using the reagents from the kit 
and the other one by traditional alkaline lysis. This last one can also be used to extract plasmids 
when it is required a large amount of recovered product. 
7.7.1 Protocol 1: using the reagents from the kit to perform alkaline lysis 
The bacterial strain was grown overnight in LB medium with the appropriate antibiotic and 
10 mL of the bacterial culture was centrifuged for 1 min at top speed in a to-table centrifuge. 
The supernatant was discarded and the cell pellet was resuspended in 250 µL of buffer P1 at 4 
o
C. The cell lysis was performed by the addition of 250 µL of lysis buffer (P2) and mixing, 
followed by the addition of 350 µL of P3 buffer. The mixture was centrifuged for 5 min at top 
speed and the supernatant was transferred to a clean 1.5 mL microcentrifuge tube. 1 volume of 
phenol:CIA was added and mixed well. Another centrifugation was performed in the same 
conditions as mentioned before. The aqueous upper phase was collected to a new 
microcentrifuge tube. 1/10 volume of 0.3 M of NaAc (pH 5.2) and 0.6 volume of isopropanol 
were then added to the recovered supernatant and the mix was incubated at room temperature 
for 15 min followed by a centrifugation at 4 
o
C, top speed for 15 min. The white pellet formed 
was washed with 1 mL of 70 % (v/v) ethanol and centrifuged 5 min at top speed. After removal 
of ethanol, the pellet was air-dried to remove residual ethanol. Finally the pellet was 
resuspended in 30 µL of sterile distilled water. 
7.7.2 Protocol 2: using the traditional alkaline lysis 
The first part of the procedure is similar to the one abovementioned. However, the cell pellet 
was resuspended in 250 µL of Solution I (instead of using the kit´s reagents) containing 100 
μg/mL of RNase A added just before use, followed by the addition of 250 μL of Solution II 
freshly prepared and 350 μL of Solution III. This mixture was centrifuged at top speed for 5 min 
and the supernatant was transferred into a clean 1.5 mL microcentrifuge tube. 1/10 volumes of 
Solution III and 0.6 volume of isopropanol were added to the recovered supernatant. The 
procedure follows as referred above when using the reagents from the kit. 
 
Solution I: 50 mM glucose, 25 mM Tris-HCl (pH= 8) and 10 mM EDTA (pH= 8) 
Solution II: 200 mM NaOH, 1% (w/v) SDS. Prepare a stock solution of NaOH (10 M) and a stock solution of 
SDS (10 %) and prepare the final solution just before use. 
Solution III: 3 M potassium acetate, pH 5.5  
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7.8 Appendix 8 
PCR using Promega Taq DNA polymerase 
To set up parallel reactions and to minimize the possibility of pipetting errors, it was 
prepared a PCR master mix by mixing water, buffer, dNTPs, primers and Promega Taq DNA 
polymerase. So all solutions were gently vortex and briefly centrifuged after thawing. A 1.5 mL 
tube was placed on ice and the following components were added for each 25 µL reaction 
(Table 10): 
Table 10 – PCR reaction using Taq DNA polymerase from Promega. 
Component of the reaction Volume 
Forward primer (10 mM) 0.75 µL 
Reverse primer (10 mM) 0.75 µL 
DNA Template*  ~ 1 µL 
5x Taq DNA Buffer 5 µL 
dNTP Mix, 10 mM each 0.5 µL 
Taq DNA polymerase (5 U/ µL) 0.125 µL 
Sterile, distilled water until 25 µL 
*To perform colony-PCR, instead of the DNA solution as template, one isolated colony is picked to the mixture. 
The required final volume is performed with distilled water. 
 
The mixture was then gently vortex, briefly centrifuged and divided into PCR tubes and a 
single colony was picked and added into the solution. The reactions were then placed in the 
thermocycler and the following thermal cycling conditions were used (Table 11): 
 
Table 11 – Thermal cycling conditions to perform the PCR with Taq DNA polymerase from Promega. 
 Temperature (
o
C) Time 
Number 
of cycles 
Initial denaturation 95 1-3 min 1 
Denaturation 95 45 s 
30 Annealing  Tm-5* 45 s 
Extension  72 1 min/kb 
Final extension 72 5-15 min 1 
*Annealing temperature based on the average of the primers melting temperatures, which was 
decreased by 5 degrees.  
 
The reaction product was stored at -20 
o
C until further use or immediately run in an 
electrophoresis gel.  
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7.9 Appendix 9 
Agarose gels handling 
7.9.1 Electrophoresis of DNA 
Analysis of DNA was generally performed on agarose gel electrophoresis. The samples were 
mixed with 6X loading buffer in a proportion of 1:6 (v/v) and loaded in a 1 % agarose gel. The 
gel was prepared with 1X of TAE buffer (Bio-Rad) and EtBr (AppliChem) to a final 
concentration of 0.5 µg/mL added before pouring the melted agarose in the running tray. In all 
gels a DNA marker was included, either 0.5 µg of the DNA Ladder Mix (Fermentas). 
Electrophoresis was generally performed at 150 V for the desired time and the DNA was 
analyzed under UV light and the image acquired in the ATTO image acquisition system. 
 
Solutions:  
Loading buffer 6X: 2.5 mg/mL of bromophenol blue, 2.5 mg/mL of xylene cyanol FF and 30 % (v/v) glycerol; 
stored at 4 oC. 
 
7.9.2 Purification of DNA from agarose gels 
The purification of DNA from agarose gels was performed using the QIAquick Gel 
Extraction Kit Protocol (Quiagen), according to the manufacturer’s instructions. Briefly: the 
desired DNA fragment was excised from the agarose gel with a clean scalpel and placed in a 1.5 
mL microcentrifuge tube. The gel slice was weighted and 3 volumes of Buffer Q1 were added 
to 1 volume of agarose (considering 100 mg as 100 mL). The tube was incubated at 50 
o
C for 10 
min (or at room temperature 1 hour) until the slice was completely dissolved. 1 volume of 
isopropanol was added and well mixed; the sample was then applied to a QIAquick spin column 
placed is a 2 mL collection tube and centrifuged at top speed for 1 min. the flow-through was 
discarded and the column was placed back to the collection tube. The DNA was washed with 
750 µL of Buffer PE and the column centrifuged as referred. The flow-though was discharged 
and the column was centrifuged for an additional minute to ensure the complete removal of 
residual ethanol. The column, containing the DNA, was placed in a clean 1.5 mL 
microcentrifuge tube and the DNA was eluted in 30 to 50 µL of sterile distilled water 
concerning the subsequent application. The elution is performed after 2 min of incubation at 
room temperature by centrifugation for 2 min at top speed. The sample was stored at -20 
o
C 
until further use. 
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7.10 Appendix 10 
Purification and concentration of PCR products and restriction digestions 
Purification and concentration of PCR products and DNA digestions were performed both 
using the (1) JETquick Purification Kit (Genomed) and (2) NZYGelpure (NZYtech), according 
to the manufacturer’s instructions. 
 
(1) JETquick Purification Kit (Genomed)  
The sample was prepared by the addition of 400 µL of solution H1 to 100 µL of PCR assay 
(this volume can be achieved by the addition of the necessary volume of sterile distilled water). 
The sample solution was loaded to a JETquick spin column placed into a 2 mL receiver tube 
and centrifuged at >12 000 xg for 1 min. The flowthrough was discarded and the column was 
washed with 500 µL of the reconstituted (with ethanol) solution H2. Another centrifugation was 
performed using the previously described conditions. The flowthrough was discarded and the 
JETquick column back into the same receiver tube and the tube was centrifuge once again at 
maximum speed for 1 min to remove the residual ethanol. Finally the column was placed into a 
clean 1.5 mL microcentrifuge tube and the DNA was eluted by the addition of 30 to 50 µL of 
sterile distilled water directly onto the center of the silica matrix of the JETquick spin column 
and centrifugation at >12 000 xg for 2 min. 
 
(2) NZYGelpure (NZYtech) 
The volume of the reaction mixture was transferred to a 1.5 mL microcentrifuge tube and 
five volumes of Binding Buffer were added and mixed well. The mixture was applied to an 
NZYTech spin column, incubated at room temperature for 2 min and centrifuged for 1 min at 
top speed. The flow-through was discarded and 600 μL of Wash Buffer were added to the spin 
column. After 2 min of room temperature incubation, the column was centrifuge for 1 min and 
the flow-through was discarded. An additional 1 min centrifugation was performed to remove 
residual ethanol.  The NZYTech spin column was then placed into a clean 1.5 mL 
microcentrifuge tube and 30 to 50 μL of sterile distilled water were added to the centre of the 
column. The DNA-containing column was incubated at room temperature for 2 min and then 
centrifuged for 1 min to elute the DNA. The sample was stored at -20 
o
C until further use. 
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7.11 Appendix 11 
Determination of RNA/DNA Concentration using Quant-iTTM assays 
(Invitrogen) 
The Quant-iT
TM
 working solution was made by diluting the Quant-iT
TM
 reagent 1:200 in 
Quant-iT
TM
 buffer (DNA or RNA reagent and buffer according to the sample to be measured). 
199 µL of the working solution were loaded into the assay tubes and 1 µL of sample was 
added (the final volume must be 200 µL). The mixture was mixed by vortexing 2-3 s and 
incubated for 2 min at room temperature. The tube was then inserted into the Qubit
TM
 
fluorometer and the concentration was calculated following the instructions on the screen. 
